

(51) International Patent Classification:
C07K 14/435 (2006.01) **G01N 33/53** (2006.01)(21) International Application Number:
PCT/US2010/057061(22) International Filing Date:
17 November 2010 (17.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/261,956 17 November 2009 (17.11.2009) US(71) Applicants (for all designated States except US): **IDEXX LABORATORIES, INC.** [US/US]; One Idexx Drive, Westbrook, ME 04092 (US). **DIVERGENCE, INC.** [US/US]; 1005 North Warson Road, Suite 401, St. Louis, MO 63132 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ELSEMORE, David, Allen** [US/US]; 29 Smokehouse Circle, South Portland, ME 04106 (US). **FLYNN, Laurie, A.** [US/US]; 60 Raymond Hill Road, Raymond, ME 04071 (US). **CRAWFORD, Michael** [US/US]; 12055 Tangletree Drive, St. Louis, MO 63146 (US). **GENG, Jinming** [CN/US]; 4 Foxcraft Drive, Scarborough, ME 04074 (US).(74) Agent: **MIAO, Emily**; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Suite 3200, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS, DEVICES, KITS AND COMPOSITIONS FOR DETECTING ROUNDWORM




FIG. 10

(57) **Abstract:** Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a mammalian sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.

METHODS, DEVICES, KITS AND COMPOSITIONS FOR DETECTING ROUNDWORM

BACKGROUND OF THE INVENTION

1. Field of the Invention

[001] The present invention relates to compositions, devices, kits and methods for the detection of roundworm in mammals. More particularly, the present invention relates to polypeptides and polypeptide compositions, antibodies and antibody compositions, devices, kits, and methods for detecting the presence or absence of roundworm antigen in a sample from a mammal that may also include one or more of hookworm, whipworm, and heartworm antigen.

2. Description of the Prior Art

[002] Adult roundworms live in the small intestine and lay eggs that pass out in the feces. In the environment, infective larvae remain within the eggs and develop into an infective stage after approximately three weeks at optimal temperatures. The infective eggs enter a host by ingestion and hatch in the small intestine. In dogs less than five weeks of age, larvae migrate through the tissue and into the bloodstream before eventually reaching the lung and trachea where additional development occurs. The host coughs up and swallows the larvae, which molt into adults that reside in small intestine. Larvae that hatch within dogs greater than five weeks of age or within other animals, including humans, are capable of traveling to a wide range of tissues including the liver, lungs, heart, brain, and skeletal muscle. These larvae subsequently arrest their development and encyst in the tissue of the host. In pregnant and lactating dogs, encysted larvae can become reactivated and cause intestinal infection in the mother, migrate to the uterus and directly infect the fetus through the placenta, or migrate to the mammary tissue and infect nursing animals. Parasitic roundworms cause disease not only in their animal hosts, but are also the etiological agents of larval migrans syndrome as well as severe enteritis and allergic reactions in humans, which occurs after ingestion of

infectious eggs from the environment or ingestion of larvae found within liver, meat or other tissues of paratenic hosts.

[003] Intestinal roundworm infection is common in animals and, if left untreated, can cause serious disease and even death. Although it is relatively easy to diagnose a roundworm-infected animal as having a parasitic worm (helminth) infection of some type, it is significantly more difficult to identify roundworm, specifically, as the causative worm. This is a problem because roundworm infections are best treated when the infected animal's caregiver has knowledge that roundworm is the specific source of the infection. In addition, humans who may come in contact with the infested animal or its excretions may be advised to take precautions against acquiring the parasite. In this context, it is important to determine the worm species with high specificity, as some helminths, such as roundworms and hookworms, can cause significant disease (*e.g.*, larva migrans) in humans, while it is generally accepted that whipworm does not play a zoonotic role of importance in humans.

[004] Current methods for diagnosis of roundworm infections primarily involve microscopic examination of fecal samples, either directly in fecal smears or following concentration of ova by flotation in density media. Despite this procedure's high adoption, the method has significant shortcomings. These microscopic methods are time consuming, are unpleasant, require specialized equipment and can have low specificity and sensitivity [Dryden *et al.*, 2005, Vet Therap. 6(1), 15-28]. In addition, the accuracy of results of these methods is highly dependent upon the skill and expertise of the operator.

[005] Stool handling is disagreeable and hazardous. Sanitary and inoffensive procedures for processing stool are awkward and often complex. Such procedures may include weighing, centrifuging and storing, and are difficult except in a clinical laboratory equipped with a suitable apparatus, protective equipment, and a skilled technician. Therefore, any reduction in the number of steps required to perform a fecal test and any reduction in contact between test operator and the test material is desirable.

Clinical laboratories have been using the immunoassay methods for the detection of various viruses, bacteria and non-helminth parasites and organisms in feces. However, there remains a need for a simple immunoassay method for the detection of a parasitic worm infection, and roundworm infection in particular in feces, whole blood or in serum.

SUMMARY OF THE INVENTION

[006] In one aspect, the invention includes antibodies that specifically bind to a polypeptide including all or an antigenic portion of the amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or copro6716, as listed herein, or to a polypeptide including a sequence that is a conservative variant of one of those sequences. In a further aspect, the antibodies specifically bind to antigen from roundworm infested mammals, but do not specifically bind antigen from mammals infected with hookworm, heartworm and/or whipworm.

[007] In another aspect, the invention includes antibodies that are obtained by immunization with the polypeptide including all or an antigenic portion of the amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or copro6716, or with a polypeptide including a sequence that is a conservative variant of one of those sequences.

[008] In yet another aspect, the invention provides a device for detecting the presence or absence of roundworm antigens from a sample; the device comprising a solid support, wherein the solid support has immobilized thereon one or more antibodies that are capable of specifically binding to a polypeptide that has an amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or copro6716, or an antigenic portion thereof. The device, may be, but is not limited to being, for example, an ELISA device, such as a lateral flow immunoassay device or microtiterplate device. Mammalian samples that may be tested for roundworm

by the device include, but are not limited to being, feces, whole blood, serum, mammary milk and whole tissue, such as tissue from mammary gland, intestine, liver, heart, lung, esophagus, brain, muscle, and eye, for example. The device further may include, but need not include, one or more reagents for the detection of one or more of the group consisting of: one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, and one or more bacteria.

[009] In yet another aspect, the invention provides a method of detecting the presence or absence of roundworm, such as *Toxocara canis* (*T. canis*), *Toxocara cati* (*T. cati*), *Toxocara vitulorum* (*T. vitulorum*), *Toxascaris leonina* (*T. leonina*), *Baylisascaris procyonis* (*B. procyonis*), *Ascaridia galli* (*A. galli*), *Parascaris equorum* (*P. equorum*), *Ascaris suum* (*A. suum*), or *Ascaris lumbricoides* (*A. lumbricoides*), *Anisakis simplex* (*A. simplex*), or *Pseudoterranova decipiens* (*P. decipiens*), for example, in a sample. The sample can be obtained from a mammal, such as a canine, feline, porcine, bovine, cetacean, pinniped or human. In one aspect, the method is carried out to test a fecal sample for roundworm coproantigen. The method, however, is not limited to being carried out to test a fecal sample. In addition to feces, the sample therefore may be, but is not limited to being whole blood, serum, mammary milk and whole tissue, such as tissue from mammary gland, intestine, liver, heart, lung, esophagus, brain, muscle, and eye, for example. Steps of the method include contacting the sample with one or more of the antibodies of the invention; forming antibody polypeptide complexes in the presence of the polypeptides if any, in the sample; and detecting the presence or absence of the antibody-polypeptide complexes, if any. The method further may include one or more of the optional steps of diagnosing the mammal as either having or not having a roundworm infection and determining whether a nucleic acid from roundworm is present in the same sample that was contacted with the antibodies for the purpose of detecting the presence or absence of roundworm or in some other sample from the mammal. The method may also be used to test for environmental contamination with roundworm. Environmental samples that may be tested for roundworm by the device include, but are not limited to soil, decomposing material, or fecal matter from residential settings including yards, gardens, sand boxes, and playgrounds. Testing locations may also include parks,

beaches, forests, farms, or other locations exposed to fecal material from dogs, cats, or other mammalian hosts of roundworms. Feces from indoor and outdoor litter boxes may also be tested.

[010] In yet another aspect, the present invention includes a kit for carrying out one or more steps of the method of the invention. The kit may optionally include, for example, the device and one or more of the compositions of the present invention and instructions for carrying out the method of the present invention. The kit may further optionally include, for example, one or more indicator reagents, one or more antibody labeling compounds, one or more antibodies, one or more antigen capture reagents, one or more inhibitors, and one or more wash reagents to be used as part of the device and/or to be used in carrying out the method.

BRIEF DESCRIPTION OF THE DRAWINGS

[011] FIG. 1 shows the nucleotide sequence of an 865-nucleotide cDNA sequence from whole adult *Toxocara canis*. (SEQ ID NO:1).

[012] FIG. 2 shows the nucleotide sequence of an 632-nucleotide cDNA sequence from whole adult *Toxocara cati*. (SEQ ID NO:2).

[013] FIG. 3 shows the amino acid sequence (SEQ ID NO:3) of a large open reading frame (ORF) of SEQ ID NO:1. The stop codon is indicated by *.

[014] FIG. 4 shows the amino acid sequence (SEQ ID NO:4) of a large ORF of SEQ ID NO:2. The stop codon is indicated by *.

[015] FIG. 5 shows a comparison alignment of SEQ ID NO:4 and SEQ ID NO:5. The consensus sequence of SEQ ID NO:4 and SEQ ID NO:5 is shown as SEQ ID NO:7.

[016] FIG. 6A shows a multi-well plate device of the present invention.

[017] FIG. 6B shows a close up of a single well of the plate of FIG. 6A with a specific antibody of the present invention immobilized thereto.

[018] FIG. 7 shows a graph of optical density (OD) values obtained from fecal samples from roundworm-infected canines by following the method of the present invention in a first Example.

[019] FIG. 8 shows a graph of OD values obtained from fecal samples from canines infected with either roundworm, hookworm or whipworm by following the method of the present invention in a second Example.

[020] FIG. 9 shows a graph of OD values obtained from fecal samples from canines infected with heartworm by following the method of the present invention in the second Example.

[021] FIG. 10 shows a microtiter plate in which an ELISA assay was carried out using fecal samples from canines infected with either roundworm, hookworm, whipworm or heartworm by following the method of the present invention in a third Example.

[022] FIG. 11 shows a graph of OD values obtained from fecal samples from a set of canines when those canines had a roundworm infection, and from fecal samples from those canines after they had been rid of roundworm, by following the method of the present invention in a fourth Example.

[023] FIG. 12 shows a graph of OD values obtained from fecal samples from roundworm-infected felines by following the method of the present invention in a fifth Example.

[024] FIG. 13 shows a first graph of OD values obtained from fecal samples from a set of felines when those felines had a roundworm infection, and from fecal samples from those felines after they had been rid of roundworm, by following the method of the present invention in a sixth Example.

[025] FIG. 14 shows a second graph of OD values obtained from fecal samples from a control set of felines that were not infected with roundworm by following the method of the present invention in the sixth Example.

[026] FIG. 15 shows an ELISA with elution fractions from a sulfopropyl (SP) column as samples, demonstrating that Copro6716 can be partially purified and enriched by eluting the SP column by following the method of the present invention in the seventh Example.

[027] FIG. 16 shows that the molecular weight of Copro6716 was about 10KD using a western blot probed with rabbit anti full-length DIV6716 IgG-HRP following the method of the present invention in the seventh Example.

[028] FIG 17. shows the amino acid sequence of the full length DIV6716 (SEQ ID NO: 5) with the four peptides (SEQ ID NOs: 8, 9, 10 and 11) identified by Mass Spectrometry analysis identified by highlighting them in the shaded boxes following the method of the present invention in the seventh Example.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

I. Introduction

[029] The present invention is generally directed to methods, devices, kits and compositions for detecting roundworm in a sample obtained from a mammal. The present invention relates to roundworm antigens from *Toxocara*, such as *Toxocara canis* or *Toxocara cati*, for example. In particular, the present invention relates to *Toxocara* polypeptides and conservative variants thereof, polynucleotides that encode those polypeptides and oligonucleotides that specifically bind to those polynucleotides, antibodies that are raised against and that specifically bind those polypeptides, and methods, devices and kits for detecting roundworm, such as *Toxocara*, *Toxascaris*,

Baylisascaris, *Ascaridia*, *Parascaris*, and *Ascaris*, *Anisakis*, or *Pseudoterranova*, including *T. canis*, *T. cati*, *T. vitulorum*, *T. leonina*, , *B. procyonis*, *A. galli*, *P. equorum*, *A. lumbricoides*, *A. suum*, *A. simplex*, or *P. decipiens*, for example.

[030] The present invention provides a superior alternative to these existing microscopic inspection techniques. This is true because the present invention provides compositions, devices, kits and methods for detecting the presence or absence of roundworm in a sample from a mammal that: (1) are both easy to use and yield consistently reliable results; (2) allow for the absence or presence of roundworm in a mammal to be confirmed regardless of whether that mammal is infected with hookworm, whipworm, and/or heartworm; and (3) can detect roundworm prior to the time that roundworm ova first appear in the infected host's feces.

[031] The present invention is based in part on the discovery of unexpected properties of compositions of the present invention. Specifically, it was determined that an antibody of the present invention raised against a polypeptide of the present invention can be used to capture and detect roundworm antigens in a mammal, even when the mammal is also infested by one or more of hookworm, whipworm and heartworm. This specificity for roundworm is surprising because roundworms, whipworms, hookworms and heartworms all are related nematodes, and an antibody raised against a protein isolated from any one of these worms would be expected to crossreact with one or more of the other worms, host antigens, or other host components.

[032] It was further determined that this antibody can be used to capture and detect roundworm antigens in a mammal as early as 17 days after the mammal is first infected with roundworm. This ability to detect roundworm so soon after infection, and before the appearance of any roundworm ova in the feces of the infected mammal, is surprising because roundworm ova generally do not appear in the feces of an infective host until about five-to-eight weeks after the host becomes infected.

[033] The present invention therefore includes methods, devices, compositions and kits that use antibodies and/or fragments thereof to specifically capture and detect

roundworm antigens in a mammal that may also be infested by one or more of whipworm, hookworm and heartworm. The ability of the present invention to detect and diagnose roundworm even when one or more other worm types are also present allows the mammal's caregiver the opportunity to optimally select a treatment for ridding the roundworm from the mammal. Further, the ability of the present invention to, in some cases, detect roundworm as early as 17 days after the mammal is first infected provides the possibility that the caregiver may begin such treatment before the mammal becomes severely sickened by the roundworm. An intervention prior to appearance of ova in the feces would also greatly reduce or eliminate the possibility that the infestation is spread to other animals or humans.

II. Definitions and Uses of Terms

[034] The term "compositions of the invention" refers to all of the nucleic acids, polypeptides, antibodies, and mixtures that include one or more of those nucleic acids, polypeptides, and antibodies and one or more other compounds, that can be used to detect the presence or absence of roundworm in a sample obtained from a mammal by carrying out the method of the present invention that are explicitly described, implicitly encompassed or otherwise disclosed herein.

[035] "A sample from a mammal" in which roundworm can be detected by the present invention includes all bodily components and extracts thereof, such as any fluid, solid, cell or tissue, that are capable of containing roundworm antigen. Exemplary samples therefore include, but are not limited to being, feces, milk, whole blood and portions thereof, including serum, and further include tissue extracts, including tissue from mammary gland, intestine, liver, heart, lung, esophagus, brain, muscle, and eye, for example. The sample may be taken directly from the mammal or the sample may be taken from anything that has contacted the mammal. For example, the sample may be fresh or decaying fecal droppings from the mammal. As another example, the sample may include soil, dirt, sand, plant material, or any other material that may be mixed with bodily components that may be left behind by a mammal, such as feces, for example. No

matter the origin or the content of the sample, this sample sometimes is referred to herein as the “mammalian sample”, the “test sample” or the “sample under test”.

[036] As used herein, “nucleic acid” is synonymous with, and therefore is used interchangeably with, “gene”, “DNA”, “cDNA”, “EST”, “polynucleotide”, “oligonucleotide”, “polynucleic acid”, “RNA” and “mRNA”. A nucleic acid may be in double-stranded form or it may be in single-stranded form. Further, a nucleic acid is either naturally isolated, such as from a whole roundworm or a portion thereof, for example, or it is artificially synthesized, either in a recombinant host organism or by any other artificial means known to the skilled artisan, such as by employing a PCR-based technique, by creating a transgenic organism that synthesizes the nucleic acid, by using a DNA synthesizing machine, or by any another molecular-based technique, for example.

[037] “Polypeptide”, “peptide” and “protein” are synonymous terms that are used interchangeably herein to refer to a polymer of amino acid residues. A polypeptide, peptide and protein of the present invention may be either naturally isolated, such as from a whole roundworm or from a portion of roundworm, for example, or artificially synthesized, either in a recombinant host organism or by any other artificial means known to the skilled artisan.

[038] The term “antibody” or “antibody of the present invention” refers to any antibody that is able to specifically bind to one or more roundworm antigens, but not to any antigen from hookworm, whipworm or heartworm. The antibodies of the present invention may be raised against one or more immunogenic polypeptides of the present invention. Unless otherwise stated, it is to be understood that the antibody of the present invention may include a mixture of two or more different types of antibody. For example, the antibody may be a mixture of two types of antibodies, wherein one of the two types specifically binds to one particular antigen and the other of the two types specifically binds to some other antigen.

[039] The “immunogenic polypeptide of the present invention” and, more simply, “the polypeptide of the present invention”, is an immunogen against which the antibodies of the present invention may be raised. All “polypeptides of the present invention” are

immunogenic and therefore may be used to elicit an immune response in a host animal to produce the antibodies of the present invention. Unless otherwise stated, it is to be understood that the polypeptide of the present invention may be one component of a mixed composition of a plurality of components.

[040] An “immunogen” is any agent, such as the immunogenic polypeptide of the present invention, for example, that is capable of eliciting an immune response in an animal that is exposed to that agent.

[041] The term “roundworm”, as used herein, refers to helminths such as intestinal roundworms of the order *Ascaridida*, which includes the genera *Toxocara*, *Toxascaris*, *Baylisascaris*, *Ascaridia*, *Parascaris*, *Ascaris*, *Anisakis*, and *Pseudoterranova*. Thus, the term “roundworm”, as used herein, does not refer to the entirety of the phylum Nematoda. Therefore, “roundworm” does not include any member of the genera *Ancylostoma*, *Uncinaria*, *Necator*, *Trichuris* or *Dirofilaria*.

[042] A “roundworm coproantigen” or a “coproantigen of roundworm” is any roundworm product that is present in the feces of a mammal having a roundworm infection and that may be specifically bound by one or more of the antibodies of the invention. For example, a roundworm coproantigen may be, but is not limited to being, one or more of the polypeptides of the invention.

[043] The present inventors have determined that a novel 10 kD isoform of DIV6716, which is a excretory/secretory protein of *T. canis*, is present in feces of *T. canis* -infected canines as early as 17 days after the canines first became infected with the *T. canis*. Therefore, a “roundworm coproantigen” may be this novel 10 kD isoform of DIV6716 (which is referred to herein as “Copro6716”) that has been observed in canine feces by the present inventors.

[044] “Specific for”, “specifically binds”, and “stably binds” means that a particular composition of the invention, such as an antibody, polypeptide, or oligonucleotide of the present invention, for example, recognizes and binds to one or more other agents with greater affinity than to at least one other agent. As one example, an antibody of the

present invention is said to be “specific for”, to “specifically bind”, and to “stably bind” roundworm antigens whenever that antibody is able to recognize and bind to those roundworm antigens with greater affinity than to any other antigens from a non-roundworm parasitic worm. Such binding specificity can be tested using methodology well known in the art, for example, ELISA or a radioimmunoassay (RIA). Based on information observed regarding the binding specificity of a particular composition of the invention, the method of the present invention can be carried out under conditions that allow that composition to bind to (and therefore to allow the detection of such binding to) a particular agent or agents, but not to significantly bind other agents, while those conditions are maintained. As one example, the method of the present invention can be carried out under conditions that allow an antibody of the present invention to bind to (and therefore to allow the detection of such binding to) one or more roundworm antigens present in a particular sample, but not significantly to any hookworm, whipworm or heartworm antigen that may be present in that sample.

[045] “Detecting roundworm” means detecting one or more roundworm-specific products, including one or more of the polypeptides, antibodies and nucleic acids of the present invention, or one or more roundworm antigens, or Copro6716, for example. The presence of one or more such roundworm products in a sample from a mammal is indicative that the mammal has a roundworm infection, regardless of whether any whole roundworm organism or ovum thereof is also present in that sample. Conversely, the absence of one or more such roundworm products a sample from a mammal is indicative that the mammal does not have a roundworm infection.

[046] “Amino acid” refers to naturally occurring and synthetic amino acids. Amino acid residues are abbreviated as follows: Alanine is A or Ala; Arginine is R or Arg; Asparagine is N or Asn; Aspartic Acid is D or Asp; Cysteine is C or Cys; Glutamic Acid is E or Glu; Glutamine is Q or Gln; Glycine is G or Gly; Histidine is H or His; Isoleucine is I or Ile; Leucine is L or Leu; Lysine is K or Lys; Methionine is M or Met; Phenylalanine is F or Phe; Proline is P or Pro; Serine is S or Ser; Threonine is T or Thr; Tryptophan is W or Trp; Tyrosine is Y or Tyr; and Valine is V or Val. Except where

defined otherwise herein, X or Xaa represents any amino acid. Other relevant amino acids include, but are not limited to being, 4-hydroxyproline and 5-hydroxylysine. In all cases, the amino acid sequence of a polypeptide described or otherwise referred to herein is presented in conventional form in that the left-most, or first, amino acid residue of the sequence is the N-terminal residue and the right-most, or last, amino acid residue of the sequence is the C-terminal residue.

[047] A “conservative variant” of any particular nucleic acid sequence includes any sequence having one or more degenerate codon substitutions to that particular nucleic acid sequence, any sequence having one or more nucleotide substitutions to, insertions to, and deletions from that particular nucleic acid sequence, and the complementary sequence of that particular nucleic acid and the conservative variants of that complementary sequence. Conservative variants of a particular nucleic acid sequence preferably have at least about 85% identity, more preferably have at least about 90% identity, and even more preferably at least about 95-99% identity, to that particular nucleic acid sequence. Conservative variants of a particular nucleic acid sequence may be artificially synthesized or they may be isolated in their natural form from an organism, including from a roundworm organism, such as *Toxocara canis* and *Toxocara cati*, for example.

[048] A “conservative variant” of any particular polypeptide sequence is any polypeptide having an amino acid sequence that varies from the amino acid sequence of that particular polypeptide but still retains the specific binding properties of that particular polypeptide, such that an antibody of the present invention that is raised against the particular polypeptide is capable of specifically binding the variant polypeptide. Therefore, for example, a conservative variant of a particular polypeptide may have one or more amino acid substitutions, deletions, additions, and insertions to that particular polypeptide. For example, a conserved variant of a particular polypeptide may have 30 or fewer, 25 or fewer, 20 or fewer, 15 or fewer, 10 or fewer, or 5 or fewer, conserved amino acid substitutions to that particular polypeptide. Conservative variants of a particular polypeptide preferably, but not essentially, have at least about 80% identity, more preferably have at least about 90% identity, and even more preferably at least about

91-99% identity, to that particular polypeptide. A percent identity for any subject nucleic acid or amino acid sequence (e.g., any of polypeptides described herein) relative to another "target" nucleic acid or amino acid sequence can be determined as follows. First, a target nucleic acid or amino acid sequence of the invention can be compared and aligned to a subject nucleic acid or amino acid sequence, using the BLAST 2 Sequences (Bl2seq) program from the stand-alone version of BLASTZ containing BLASTN and BLASTP (e.g., version 2.0.14). The stand-alone version of BLASTZ can be obtained at www.ncbi.nlm.nih.gov. Instructions explaining how to use BLASTZ, and specifically the Bl2seq program, can be found in the 'readme' file accompanying BLASTZ. The programs also are described in detail by Karlin et al. (1990) Proc. Natl. Acad. Sci. 87:2264; Karlin et al. (1990) Proc. Natl. Acad. Sci. 90:5873; and Altschul et al. (1997) Nucl. Acids Res. 25:3389.

[049] "Copro6716" refers to a 10kD portion of DIV6716 found in mammalian feces.

[050] Bl2seq performs a comparison between the subject sequence and a target sequence using either the BLASTN (used to compare nucleic acid sequences) or BLASTP (used to compare amino acid sequences) algorithm. Typically, the default parameters of a BLOSUM62 scoring matrix, gap existence cost of 11 and extension cost of 1, a word size of 3, an expect value of 10, a per residue cost of 1 and a lambda ratio of 0.85 are used when performing amino acid sequence alignments. The output file contains aligned regions, of homology between the target sequence and the subject sequence. Once aligned, a length is determined by counting the number of consecutive nucleotides or amino acid residues (*i.e.*, excluding gaps) from the target sequence that align with sequence from the subject sequence starting with any matched position and ending with any other matched position. A matched position is any position where an identical nucleotide or amino acid residue is present in both the target and subject sequence. Gaps of one or more residues can be inserted into a target or subject sequence to maximize sequence alignments between structurally conserved domains (*e.g.*, α -helices, β -sheets, and loops).

[051] The percent identity over a particular length is determined by counting the number of matched positions over that particular length, dividing that number by the length and multiplying the resulting value by 100. For example, if (i) a 500 amino acid target sequence is compared to a subject amino acid sequence, (ii) the BL2seq program presents 200 amino acids from the target sequence aligned with a region of the subject sequence where the first and last amino acids of that 200 amino acid region are matches, and (iii) the number of matches over those 200 aligned amino acids is 180, then the 500 amino acid target sequence contains a length of 200 and a sequence identity over that length of 90% (*i.e.*, $180/200 \times 100 = 90$). It will be appreciated that a nucleic acid or amino acid target sequence that aligns with a subject sequence can result in many different lengths with each length having its own percent identity. It is noted that the percent identity value can be rounded to the nearest tenth. For example, 78.11, 78.12, 78.13, and 78.14 is rounded down to 78.1, while 78.15, 78.16, 78.17, 78.18, and 78.19 is rounded up to 78.2. It is also noted that the length value will always be an integer.

[052] Conservative variants of a particular polypeptide sequence may be artificially synthesized or they may be isolated in their natural form from an organism, including from a roundworm organism, such as *Toxocara canis* and *Toxocara cati*, for example. In one specific example, the polypeptide of the invention having an amino acid sequence corresponding to SEQ ID NO:4 shown below is a conservative variant of the polypeptide of the present invention having an amino acid sequence corresponding to SEQ ID NO:3 in that SEQ ID NO:4 is more than 92% identical to SEQ ID NO:3 over an alignment of 131 amino acids. More generally, each one of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 are conserved variants of each other. It is also to be understood that other conserved variants of the SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 are contemplated by the present invention as described herein, but the skilled artisan would recognize that all of these contemplated variants are too numerous to list. The skilled artisan will also recognize that these variants include, but are not limited to, those have one or more substitutions of basic amino acid residues, one or more substitutions of acidic amino acid residues, one or more substitutions of polar amino acid residues, one or more substitutions of hydrophobic

amino acid residues, one or more substitutions of aromatic amino acid residues, and one or more substitutions of small amino acid residues. (“Basic” amino acid residues are K, R and H. “Acidic” amino acid residues are D and E. “Polar” amino acid residues are N and Q. “Hydrophobic” amino acids are I, L, and V. “Aromatic” amino acid residues are F, Y, and W. “Small” amino acids are G, S, A, T and M.)

III. Nucleic Acids and Polypeptides of the Invention

[053] The nucleic acids and polypeptides of the invention are described in detail in Provisional Application: “Methods, Devices, Kits And Compositions For Detecting Roundworm,” Application Serial No. 61/128,079, filed May 19, 2008, and is incorporated by reference in its entirety.

[054] In an attempt to identify compositions that may be used to confirm the presence or absence of roundworm in a fecal sample, a plurality of oligonucleotide primers corresponding to portions of two expressed sequence tag (EST) clones (ko15fo7 and ko34f08; which are available from the Washington University Genome Sequencing Center, St. Louis, MO) were designed, synthesized and used in 5’ RACE, 3’RACE and RT-PCR reactions that included total RNA isolated from either *Toxocara canis* or *Toxocara cati*. As a result of these efforts, an 865-nucleotide cDNA sequence was deduced from *Toxocara canis* (this sequence is shown in FIG. 1 and is identified herein as SEQ ID NO:1), and a 632-nucleotide cDNA sequence was deduced from *Toxocara cati* (this sequence is shown in FIG. 2 and is identified herein as SEQ ID NO:2). (BLAST searches that were carried out using SEQ ID NO:1 indicated that a portion of that sequence is similar to, but is not identical to or substantially identical to, nucleic acid sequence that is predicted to encode a portion of the TBA-1 protein of *Toxocara canis* and to nucleic acid sequence that is predicted to encode the ABA-1 protein of *Ascaris lumbricoides* (see S. Yahiro et al., *Parasite Immunology* 20:351-7 (1998); M. W. Kennedy, *Parasitology Today* 16:373-80 (2000); and Y. Xia et al., *Parasitology* 120:211-24 (2000).)

[055] Analysis of the sequences corresponding to SEQ ID NO:1 and SEQ ID NO:2 indicated that each one of these sequences contains a large ORF. Specifically, as shown in FIG. 3, the large ORF of SEQ ID NO:1 corresponds to nucleotides 2 through 616 of SEQ ID NO:1 and is predicted to encode a polypeptide having the following amino acid sequence:

KKIYGVAASRRRRHHFTLENSLDTHLKWLSHEQKEELLQMKKDGKSKKELQDKI
MHYYEHLEGDAKHEATEQLKGGCREILKHVVGEEKAAEIKALKDSGASKDELK
AKVEEALHAVTDEEKKQHIAEFGPACKKIYGVAASRRRRHHFTLENSLDTHLKW
LSHEQKEELLQMKKDGKSKKELQDKIMHYYEHLEGMLLALCILY (SEQ ID
NO:3).

[056] Further, as shown in FIG. 4, the large ORF of SEQ ID NO:2 corresponds to nucleotides 1 through 486 of SEQ ID NO:2 and is predicted to encode a polypeptide having the following amino acid sequence:

IYGVAASRRRRHHFTLEKSLDTHLKWLSHEQKEELLKMKKDGKSKKELQDKVM
HFYEHLEGDAKHEATEQLKGGCREILKHVVGEEKAAEIKALKDSGASKDELKAK
VEDALHAVTDEEKKQHIAEFGPACKEIFGVPIIDVRHKRDPYTNMTPDEVAEGLRS
(SEQ ID NO:4).

[057] The polypeptides of the present invention may be encoded for by nucleic acids that have a nucleotide sequence that corresponds to all or portions of SEQ ID NO:1 and SEQ ID NO:2 or to all or portions of any conservative variant of those sequences. It is to be understood therefore that the amino acid sequence of the polypeptide of the present invention is variable.

[058] For example, the polypeptide of the present invention may have an amino acid sequence that corresponds to all or a portion of SEQ ID NO:3 or SEQ ID NO:4 or all or a portion of any conservative variant of SEQ ID NO:3 or SEQ ID NO:4.

[059] In one specific example, the polypeptide of the present invention has the following amino acid sequence:

MHHFTLENSLDTHLKWLSHEQKEELLQMKKDGKSKKELQDKIMHYEHLLEGD
AKHEATEQLKGGCREILKHVVGEEKAAEIKALKDSGASKDELKAKVEEALHAVT
DEEKKQHIAEFGPACKKIYGVAAS (SEQ ID NO:5).

[060] With 130 amino acids, protein DIV6716 (SEQ ID NO:5) is about 14 kD in size. The present inventors have determined that a truncated portion (about 10 kDa) of the full-length (14 kDa) protein, and therefore not the 14 kDa version, is present in the feces of canines that are infected by *T. canis*. (This 10 kDa truncated portion of DIV6716 is referred to herein as “Copro6716”; the detection of Copro6716 in feces of *T. canis*-infected canines is described in the Example section included herein.) In one aspect, therefore, the present invention provides polypeptides that may be used to generate antibodies that may be used to specifically capture and detect Copro6716.

[061] The 129 amino acid residues that follow the N-terminal methionine residue of the polypeptide corresponding to SEQ ID NO:5 (DIV 6716) specifically represent the amino acid residues 14 through 142 of SEQ ID NO:3. As described in the Example section included herein, the N-terminal methionine was artificially added to the N-terminus of this polypeptide by carrying out a standard cloning technique. Also as described throughout the Example section, antibody raised against the polypeptide corresponding to SEQ ID NO:5 was useful for detecting roundworm antigen. Because the N-terminal methionine was artificially added, and is not thought to naturally exist in *Toxocara* (the residue that is immediately prior to the histidine residue at position 14 in each one of SEQ ID NO:3 and SEQ ID NO:4 is arginine, and not methionine), it is therefore contemplated that the polypeptide of the present invention may have an amino acid sequence that corresponds to amino acid residues 14 through 142 of SEQ ID NO:3, or, more specifically:

HHFTLENSLDTHLKWLSHEQKEELLQMKKDGKSKKELQDKIMHYEHLLEGDAK
HEATEQLKGGCREILKHVVGEEKAAEIKALKDSGASKDELKAKVEEALHAVTDE
EKKQHIAEFGPACKKIYGVAAS (SEQ ID NO:6).

[062] Further, an alignment of SEQ ID NO:5 (mostly *Toxocara canis*-derived sequence; with the only exception being the N-terminal methionine residue) to SEQ ID NO:4 (*Toxocara cati*-derived sequence) is shown in FIG. 5. Because antibody raised against a polypeptide having sequence corresponding to SEQ ID NO:5 was useful for detecting *Toxocara cati* (see the Example section included herein), it is additionally contemplated that the polypeptide of the present invention may have the amino acid sequence corresponding to SEQ ID NO:7 (which also is shown in FIG. 5), wherein the X at position 1 is I or absent, the X at position 2 is Y or absent, the X at position 3 is G or absent, the X at position 4 is V or absent, the X at position 5 is A or absent, the X at position 6 is A or absent, the X at position 7 is S or absent, the X at position 8 is R or absent, the X at position 9 is R or absent, the X at position 10 is R or absent, the X at position 11 is R or M, the X at position 18 is N or K, the X at position 37 is Q or K, the X at position 52 is I or V, X at position 55 is Y or F, the X at position 110 is E or D, the X at position 133 is K or E, the X at position 135 is Y or F, the X at position 138 is A or P, the X at position 139 is A or I, the X at position 140 is S or D, the X at position 141 is V or absent, the X at position 142 is R or absent, the X at position 143 is H or absent, the X at position 144 is K or absent, the X at position 145 is R or absent, the X at position 146 is D or absent, the X at position 147 is P or absent, the X at position 148 is Y or absent, the X at position 149 is T or absent, the X at position 150 is N or absent, the X at position 151 is M or absent, the X at position 152 is T or absent, the X at position 153 is P or absent, the X at position 154 is D or absent, the X at position 155 is E or absent, the X at position 156 is V or absent, the X at position 157 is A or absent, the X at position 158 is E or absent, the X at position 159 is G or absent, the X at position 160 is L or absent, the X at position 161 is R or absent, and the X at position 162 is S or absent.

[063] It is also contemplated that any one or more of the SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 may be only a portion of a larger polypeptide sequence, and therefore may represent partial sequence of one or more proteins that normally are expressed in roundworm, for example, or one or more polypeptide sequences that are artificially fused to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716. The skilled artisan will recognize

that are a variety of techniques exist for artificially fusing two or more polypeptide fragments together.

[064] It is even further contemplated that the polypeptide of the present invention may include more than one of the SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and Copro6716. For example, the polypeptide of the present invention may include the SEQ ID NO:5 fused to the SEQ ID NO:7. Also, it is contemplated that the polypeptide of the present invention may include a plurality of polypeptide fragments corresponding to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and Copro6716. For example, the polypeptide of the present invention may be formed by a plurality of polypeptide fragments corresponding to SEQ ID NO:5 that are fused together. In another example, the polypeptide of the present invention may be formed by a plurality of polypeptide fragments corresponding to SEQ ID NO:5 and a plurality of polypeptide fragments corresponding to SEQ ID NO:7 that are fused together in any combination.

[065] Whereas one particular polypeptide of the present invention was expressed and isolated by a specific technique (in which is described in the Example section included herein), the skilled artisan will recognize that any of the polypeptides of the present invention may be isolated by employing any one or more of a variety of techniques. (See, *e.g.*, Sewald and Jakubke, *Peptides: Chemistry and Biology*, Wiley Publishing (2002); *Peptide Synthesis and Applications (Methods in Molecular Biology)* Howl, ed., Humana Press (2005); Jones, *Amino Acid and Peptide Synthesis*, Oxford University Press (2002), each one of which is incorporated herein by reference in its entirety.) These techniques include those that may be carried out to isolate naturally existing polypeptides such as Copro6716 or polypeptides having amino acid sequence corresponding to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 and any naturally occurring variant of those polypeptides. These techniques further include those that may be carried out to artificially generate the polypeptides having amino acid sequence corresponding to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7 and any conserved variant of those polypeptides such as Copro6716 or

polypeptides. Such variants may be generated, for example, by employing any one or more mutagenesis techniques or by direct synthesis.

[066] The polypeptides of the present invention are capable of eliciting an immune response in a host animal that is exposed to these polypeptides to produce one or more of the antibodies of the present invention. Regardless of the technique by which they are derived, the polypeptides of the present invention are preferably prepared in substantially pure form when they are to be used for the purpose of raising antibody. Preferably, these polypeptides are at least about 80% pure, more preferably are at least about 90-95% pure, and even more preferably are at least about 99% pure. Exemplary techniques for eliciting an immune response in a host organism and for isolating antibodies therefrom are described herein, but it is to be understood that the present invention is not limited to those techniques. The skilled artisan will recognize that there are a plurality of techniques for achieving this same goal without deviating from the scope and spirit of the invention.

IV. Antibodies of the Invention

[067] The present invention further includes antibodies and antigen-binding fragments thereof that are raised against and that specifically bind all or part of one or more polypeptides of the present invention, and also includes compositions that include said antibodies and antigen-binding fragments thereof. When contacted to a sample obtained from a mammal, these antibodies and antigen-binding fragments are able to specifically bind roundworm antigen present in the sample, but are not able to specifically bind any antigen from hookworm, whipworm, or heartworm that may be present in the sample. The antibodies of the present invention are suitable for being used only to capture one or more roundworm antigens, only to detect one or more roundworm antigens, or more preferably, to both capture and detect one or more roundworm antigens.

[068] The antibodies of the present invention may belong to any antibody class, including for example, IgG, IgM, IgA, IgD and IgE, and may be prepared by any of a variety of techniques known to the skilled artisan. (See, *e.g.*, Dean, *Methods Mol. Biol.*

80:23-37 (1998); Dean, *Methods Mol. Biol.* 32:361-79 (1994); Baileg, *Methods Mol. Biol.* 32:381-88 (1994); Gullick, *Methods Mol. Biol.* 32:389-99 (1994); Drenckhahn *et al. Methods Cell. Biol.* 37:7-56 (1993); Morrison, *Ann. Rev. Immunol.* 10:239-65 (1992); Wright *et al. Crit. Rev. Immunol.* 12:125-68(1992); Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory (1988); and *Making and Using Antibodies: A Practical Handbook*, Howard and Kaser, eds., CRC Press (2006), each one of which is incorporated herein by reference in its entirety.)

[069] In one technique, the polypeptide of the invention is introduced into a host animal, such as into rabbit, mouse, rat, guinea pig, goat, pig, cow, sheep, donkey, dog, cat, chicken, or horse, for example. An enhanced immune response may be elicited in the host animal by associating the polypeptide with a carrier and/or by exposing the host to an adjuvant, but it is to be understood that the present invention does not require that the polypeptide be associated with a carrier or that the host be exposed to the adjuvant. An exemplary carrier that may be used for this purpose is bovine serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Exemplary adjuvants include Freund's complete or incomplete adjuvant and MDL-TDM adjuvant. Regardless of whether the polypeptide is associated with such a carrier or whether the host is exposed to an adjuvant, booster immunizations optionally may be made with the host animal being bled one or more times thereafter. Polyclonal antibodies that specifically bind the polypeptide may then be purified from antisera obtained from the bleed or bleeds. Such purification may be achieved, for example, by employing affinity chromatography techniques that involve associating the polypeptide to a solid support. Such affinity chromatography techniques are well known by the skilled artisan.

[070] In one embodiment, the antibody of the present invention is an antibody that is raised in rabbit by immunizing that host animal with the polypeptide having the amino acid sequence corresponding to SEQ ID NO:5. (Hereinafter, this particular antibody is referred to as "anti-DIV6716".) A specific technique for producing and isolating anti-DIV6716 pAB is described in the Example section included herein, but the skilled artisan will recognize that the production and isolating of anti-DIV6716 pAB, or any other antibody of the present invention, is not limited to that specific technique.

[071] In other embodiments, the antibody of the present invention is raised in a host against one or more polypeptides having an amino acid sequence that is a conservative variant of the sequence corresponding to SEQ ID NO:5. In some other embodiments, the antibody of the present invention is raised in a host against any one or more polypeptides having an amino acid sequence corresponding to the sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, or one or more polypeptides having an amino acid sequence that is a conservative variant of any of those sequences.

[072] In another embodiment, the antibody of the present invention is an antibody that specifically binds Copro6176 and/or one or more the polypeptide having the amino acid sequence corresponding to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, or antigenic portions thereof.

[073] In yet other embodiments, the antibody of the present invention specifically binds one or more polypeptides having an amino acid sequence that is a conservative variant of Copro6176 or of the sequence corresponding to SEQ ID NO:5. In some other embodiments, the antibody of the present invention specifically binds one or more polypeptides having an amino acid sequence corresponding to the sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, or one or more polypeptides having an amino acid sequence that is a conservative variant of any of those sequences.

[074] It is also to be understood that the antibodies of the invention may be polyclonal or monoclonal antibodies, single chain antibodies (scFv), chimeric antibodies, and fragments thereof. Monoclonal antibodies that are specific for the polypeptide of interest may be obtained and purified, for example, by preparing cell lines that generate antibodies having the desired specificity to the polypeptide of interest. Cell lines of this kind may be derived from cells of a particular type (*e.g.*, spleen cells) that are isolated from a host animal that had previously been immunized with the polypeptide as described before. In such a case, these cells could then be immortalized, for example, by fusing them with myeloma cells by carrying out any one of a variety of fusion techniques known to the skilled artisan. In one exemplary technique, the cells from the immunized host

animal are co-incubated with their fusion partner, *e.g.*, the myeloma cells, in the presence of a detergent for a short period of time before being plated on a medium that supports the growth of hybrid cells (but not the myeloma fusion partner). Such selection may be achieved, for example, by using hypoxanthine, aminopterin, and thymidine (HAT). When hybrid cells emerge during selection, in perhaps one or two weeks after commencing the selection process, single hybrid colonies (and their supernatants) are tested for their ability to bind the polypeptide or polypeptides against which the host animal was immunized. Hybrid colonies having the most optimal binding specificity would represent the best candidates from which monoclonal antibodies may be isolated. These monoclonal antibodies, for example, may be isolated directly from the supernatant (*i.e.*, medium) in which these colonies are grown by employing any one of a variety of techniques known to the skilled artisan.

[075] The antibodies of the invention also may be a single chain antibody (scFv), or an antigen binding fragment of an antibody. Antigen-binding fragments of antibodies are a portion of an intact antibody comprising the antigen binding site or variable region of an intact antibody, wherein the portion is free of the constant heavy chain domains of the Fc region of the intact antibody. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab')₂ and F_v fragments. In addition to production and purification from animals or mammalian cells, antibodies, antibody fragments, or non-antibody scaffolds can be selected based upon various *in vitro* technologies, including phage display, ribosomal display, or bacterial display.

[076] Antibodies, including secondary antibodies, may be labeled with any type of label known in the art, including, for example, fluorescent, chemiluminescent, radioactive, enzymes, colloidal particles, radioisotopes and bioluminescent labels. In various embodiments of the invention, the one or more of the antibodies of the invention are labeled with an enzyme, a colloidal particle, a radionuclide or a fluorophor. The particulate label can be, for example, a colored latex particle, dye sol, or gold sol conjugated to an antibody.

V. Methods, Devices and Kits of the Invention

A. Devices and Kits of the Invention

[077] The present invention, in one aspect, is a device for the detection of roundworm infection in a mammal, such as a canine, feline, porcine, bovine, or human, for example. The device is arranged to aid in the detection of the presence or absence of roundworm antigen in a sample from a mammal that may also be infected with one or more other worm parasites, including hookworm, whipworm, and heartworm.

[078] In one aspect, the device includes a solid support, wherein one or more antibodies of the invention are immobilized on the solid support. The solid support may be, but is not limited to being, the inner, bottom surface of a well of a microtiter plate or a substrate that is included as part of a lateral flow device, for example. An exemplary microtiter plate is an Immulon 1B 96-well plate (which is commercially available from Thermo Scientific of Milford, MA), but it is to be understood that the skilled artisan will recognize that a large variety of other microtiter plates that are not the Immulon 1B 96-well plate allow for the immobilization of antibodies thereon, and therefore would be suitable for providing the solid support of the present invention.

[079] An exemplary lateral flow device is the lateral flow device that is described in US Patent No. 5,726,010, which is incorporated herein by reference in its entirety. The device for performing a lateral flow assay may be a SNAP® device, which is commercially available from IDEXX Laboratories, Inc. of Westbrook, ME. However, it is to be understood that the skilled artisan will recognize that a large variety of other lateral flow devices that are not SNAP® devices or described by US Patent No. 5,726,010 allow for the immobilization of an antibody thereon, and therefore would be suitable for being used as the device of the present invention. These devices can include, for example, lateral flow devices that use colloidal gold technology.

[080] Antibodies used in the device of the invention may be immobilized on the solid support by any methodology known in the art, including, for example, covalently or non-

covalently, directly or indirectly, attaching the antibodies to the solid support. Therefore, while these antibodies may be attached to the solid support by physical adsorption (*i.e.*, without the use of chemical linkers), it is also true that these antibodies may be immobilized to the solid support by any chemical binding (*i.e.*, with the use of chemical linkers) method readily known to one of skill in the art.

[081] It is also to be understood that the solid support may be any suitable material for the immobilization of the antibodies of the invention. For example, the solid support may be beads, particles, tubes, wells, probes, dipsticks, pipette tips, slides, fibers, membranes, papers, natural and modified celluloses, polyacrylamides, agaroses, glass, polypropylene, polyethylene, polystyrene, dextran, nylon, amylases, plastics, magnetite or any other suitable material readily known to one of skill in the art.

[082] The device optionally may include one or more labeled antigen capture reagents that may be mixed with a sample from a mammal prior to application to a device of the invention. When the labeled capture antigen reagent is included, the labeled antigen capture reagent may or may not be deposited or dried on a solid surface of the device. “Antigen capture reagent” refers to any compound that is specific for the antigen or antigens of interest. The labeled antigen capture reagent, whether added to the mammalian sample or pre-deposited on the device, may be, for example, a labeled antibody specific for a roundworm antigen, including, but not limited to, the antibodies of the present invention. In just one example, anti-DIV6716 pAB or anti-Copro6716 conjugated with horseradish peroxidase may be used as a labeled antigen capture reagent.

[083] The device also may optionally include a liquid reagent that transports (such as when the device is a SNAP® device, for example), or otherwise facilitates removal of (such as when the device includes a microtiter plate, for example), unbound material (*e.g.*, unreacted portions of the mammalian sample, such as, for example, unreacted portions of fecal extract, and unbound antigen capture reagent) away from the reaction zone (solid phase). The liquid reagent may be a wash reagent and serve only to remove unbound material from the reaction zone, or it may include a detector reagent and serve

to both remove unbound material and facilitate antigen detection. For example, in the case of an antigen capture reagent conjugated to an enzyme, the detector reagent includes a substrate that produces a detectable signal upon reaction with the enzyme-antibody conjugate at the reaction zone (solid phase). Alternatively, in the case of a labeled antigen capture reagent conjugated to a radioactive, fluorescent, or light-absorbing molecule, the liquid reagent acts merely as a wash solution facilitating detection of complex formation at the reactive zone by washing away unbound labeled reagent.

[084] The liquid reagent may further include a limited quantity of an "inhibitor", *i.e.*, a substance that blocks the development of the detectable end product. A limited quantity is defined as being an amount of inhibitor sufficient to block end product development until most or all excess, unbound material is transported away from the second region, at which time detectable end product is produced.

[085] The device of the present invention may also include various binding reagents immobilized at locations distinct from the antigen capture reagent or reagents. For example, an immunoreagent (an antibody, antigen or polypeptide) that recognizes a species-specific (*e.g.*, roundworm-specific) antibody portion of a labeled antibody or antigen capture reagent, or an enzyme portion of an enzyme-labeled reagent, can be included as a positive control to assess the viability of the reagents within the device. For example, a positive control may be an anti-horseradish peroxidase antibody that has been raised in, for example, goat or mouse. Additionally, a reagent, *e.g.*, an antibody, isolated from a non-immune member of the species from which the antibody portion of the antigen-antibody complex was derived can be included as a negative control to assess the specificity of immunocomplex (*i.e.*, antigen-antibody complex) formation.

[086] In addition to being designed to detect roundworm in a mammalian sample, the device of the invention optionally may be designed to allow one or more other diagnostic tests to be performed. For example, the solid support may also include reagents for the detection of one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, or one or more bacteria. The reagents

for the detection of one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, or one or more bacteria may be, for example, one or more antibodies or one or more antigens recognized by antibodies specific for one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, or one or more bacteria.

[087] In one embodiment, which is shown in FIGS. 6A and 6B, the device of the present invention is a microtiter plate 10 that includes a plurality of wells 12, wherein each well 12 includes a solid support 14 having anti-DIV6716 pAB (represented as element 16) immobilized thereupon.

[088] The plate 10 may be used in conjunction with a method of the present invention to detect roundworm in a mammalian sample. Specifically, a roundworm infection may be diagnosed in a mammal by detecting one or more roundworm antigens with the anti-DIV6716 pAB that is immobilized on the solid support 14. In one embodiment, the antigens that are detected are roundworm coproantigens. "Roundworm coproantigens" are any product or products of roundworm that are present in a fecal sample and that can specifically and stably bind to the anti-DIV6716 pAB or anti-Copro6716. Roundworm coproantigens therefore may be whole roundworm, roundworm eggs, roundworm fragments, or products secreted, excreted or shed from roundworm or a combination thereof. Roundworm coproantigens further include the polypeptides of the present invention, such as Copro6716 and the polypeptides having an amino acid sequence corresponding to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, polypeptides having an amino acid sequence that is a conservative variant of those sequences, and/or antigenic fragments of any such polypeptides and/or antigenic fragments of any such polypeptides, for example. An exemplary roundworm coproantigen is Copro6716 that was detected by the present invention in fecal samples obtained from roundworm-infected canines as described herein.

[089] The invention further includes assay kits (*e.g.*, articles of manufacture) for detecting roundworm in a mammalian sample. A kit therefore may include one or more

devices and/or compositions of the present invention. For example, the kit may include anti-roundworm antibodies and means for determining binding of the antibodies to roundworm antigens in the sample. In one particular example, such a kit includes the device having an immobilized anti-roundworm antibody, such as anti-DIV6716 pAB or anti-Copro6716 pAB, for example, one or more antigen capture reagents (*e.g.*, a non-immobilized labeled antigen capture reagent and an immobilized antigen capture reagent) and wash reagent, as well as detector reagent and positive and negative control reagents, if desired or appropriate. Other components such as buffers, controls, and the like, known to those of ordinary skill in art, may be included in such test kits. The relative amounts of the various reagents can be varied, to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of the assay. Particularly, the reagents can be provided as dry powders, usually lyophilized, which on dissolution will provide for a reagent solution having the appropriate concentrations for combining with a sample. The present kit may further include instructions for carrying out one or more methods of the present invention, including instructions for using any device and/or composition of the present invention that is included with the kit.

B. Methods of the Invention

[090] The present invention further includes methods for using one or more of the devices, kits and/or compositions of the present invention to detect the presence or absence of roundworm in a sample. The methods therefore may be carried out to detect the presence or absence of roundworm in a sample, such as, for example, a fecal sample, that is obtained from a mammal, including, but not limited to, a canine, feline, porcine, bovine or human. Further, the methods may be carried out to detect *Toxocara*, such as *T. canis* or *T. cati*, or *T. vitulorum*, for example. It is to be understood, however, that these methods are not limited to being used to detect *Toxocara*, and therefore these methods may be carried out for the purpose of detecting other species of roundworm, such as *Toxascaris*, including *T. leonina*, *Baylisascaris*, including *B. procyonis*, *Ascaridia*, including *A. galli*, *Parascaris*, including *P. equorum*, *Ascaris*, including *A. lumbricoides* and *A. suum*, *Anisakis*, including *Anisakis simplex*, or *Pseudoterranova*, including *P.*

decipiens, for example. These methods further are useful for confirming such presence or absence of roundworm in a sample even when that sample includes one or more products derived from other worm species, including one or more products from hookworm, whipworm, and/or heartworm.

[091] In the methods of the present invention, detection of roundworm may be accomplished by detecting the presence or absence of one or more roundworm antigens, such as Copro6716 or the polypeptides having an amino acid sequence corresponding to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7, as well as antigenic fragments and/or conservative variants of those sequences, for example. When the sample under test for roundworm is feces, the soluble portion of the feces may be collected by any protocol known in art. For example, in addition to the specific protocol described in the Example section herein, the soluble portions of the sample generally may be collected by using filtration, extraction, centrifugation, or simple mixing followed by gravimetric settling. The skilled artisan will recognize that there are a variety of ways of extracting and preparing non-fecal samples from a mammal as well. For example, the sample may be a bodily fluid that is naturally excreted or otherwise released by the mammal or that is artificially obtained from the mammal. Such artificial extraction may be carried out by milking the mammal or by injecting a syringe into the mammal and drawing the fluid into the syringe. Once obtained, the fluid optionally may be fractionated (for example, serum may be fractionated from whole blood as then used as the sample). As another example, the sample may be obtained by swabbing the mammal, such as the oral cavity of the mammal, for example. As yet another example, tissue sections may be obtained by biopsy.

[092] The methods include contacting the mammalian sample with one or more antibodies specific for one or more roundworm antigens under conditions that allow an antigen/antibody complex, *i.e.*, an immunocomplex, to form. That is, an antibody specifically binds to a roundworm antigen present in the sample. The skilled artisan is familiar with assays and conditions that may be used to detect such antigen/antibody complex binding. For example, the antigen/antibody complex may be detected using a

secondary antibody that binds to the antigen/antibody complex. The formation of a complex between roundworm antigen and anti-roundworm antibodies in the sample may be detected using any suitable method known in the art.

[093] Further, the relative amount of antibody-antigen complexes that are formed in one particular reaction may be measured with respect to those formed in any other reaction by any methodology known in the art for achieving that goal. When it is determined that a sample under test has more antibody-antigen complexes than does a control sample, it can be concluded that roundworm is present in the test sample. When this is true, it may be concluded that the mammal from which the test sample was obtained harbors an intestinal roundworm infection. Either one or both of the conclusions that roundworm is present in the test sample and that the mammal being tested harbors an intestinal roundworm infection may be made by a clinician at a diagnostic service provider or by a caregiver of the mammal, such as the mammal's veterinarian, for example. When a caregiver of a mammal determines (or is otherwise informed that) a mammal harbors a roundworm infection, the caregiver may then subject the mammal to a course of treatment that is optimally designed to rid the mammal of roundworm specifically, rather than of a parasitic nematode infection generally. In addition, humans who may come in contact with the infested animal or its excretions may be advised to take precautions against acquiring the parasite. In this context, it is important to determine the worm species with high specificity, as some helminths, such as roundworms and hookworms, can cause significant disease (*e.g.*, larval migrans) in humans, while it is generally accepted that whipworm does not play a zoonotic role of importance in humans. Further, the present invention can be used to confirm that any animal that has received treatment for a roundworm infection has been rid of that infection.

[094] The steps of the method of the present invention may include applying a mammalian sample to a device of the invention, which includes an immobilized antibody specific for one or more roundworm antigens, and detecting the presence or absence of the roundworm antigen in the sample. Antibodies specific for antigens of roundworms

may be directly or indirectly attached to a solid support or a substrate such as a microtiter well, antibody-immobilizing portion of a SNAP® device, magnetic bead, non-magnetic bead, column, matrix, membrane, fibrous mat composed of synthetic or natural fibers (*e.g.*, glass or cellulose-based materials or thermoplastic polymers, such as, polyethylene, polypropylene, or polyester), sintered structure composed of particulate materials (*e.g.*, glass or various thermoplastic polymers), or cast membrane film composed of nitrocellulose, nylon, polysulfone or the like (generally synthetic in nature). All of these substrate materials may be used in suitable shapes, such as films, sheets, or plates, or they may be coated onto or bonded or laminated to appropriate inert carriers, such as paper, glass, plastic films, or fabrics. Suitable methods for immobilizing peptides on solid phases include ionic, hydrophobic, covalent interactions and the like.

[095] The methods of the present invention do not require the use of solid phases or substrates, however. The skilled artisan will recognize that there are a number of ways that the present method may be carried out to detect the presence or absence of roundworm without involving the use of solid phases or substrates. In just one example, immunoprecipitation methods that do not require the use of solid phases or substrates may be carried out.

[096] In some embodiments of the invention, the antigen/antibody complex is detected when an indicator reagent, such as an enzyme conjugate, which is bound to the antibody, catalyzes a detectable reaction. Optionally, an indicator reagent including a signal generating compound may be applied to the antigen/antibody complex under conditions that allow formation of a detectable antigen/antibody/indicator complex. Optionally, the antibody may be labeled with an indicator reagent prior to the formation of an antigen/antibody complex.

[097] The formation of an antigen/antibody complex or an antigen/antibody/indicator complex in some of the methods of the present invention specifically may be detected by radiometric, colorimetric, fluorometric, photometric, size-separation, or precipitation methods. Detection of an antigen/antibody complex also may be accomplished by the

addition of a secondary antibody that is coupled to an indicator reagent including a signal generating compound. Indicator reagents including signal generating compounds (labels) associated with a polypeptide/antibody complex may be detected using the methods described above and may include chromogenic agents, catalysts such as enzyme conjugates, fluorescent compounds such as fluorescein and rhodamine, chemiluminescent compounds such as dioxetanes, acridiniums, phenanthridiniums, ruthenium, and luminol, radioactive elements, direct visual labels, as well as cofactors, inhibitors, magnetic particles, and the like. Examples of enzyme conjugates include alkaline phosphatase, horseradish peroxidase, beta-galactosidase, and the like. The selection of a particular label is not critical, but it will be capable of producing a signal either by itself or in conjunction with one or more additional substances.

[098] Methods of the invention include, but are not limited to those based on competition, direct reaction or sandwich-type assays, including, but not limited to ELISA, RIA, immuno-fluorescent assays (IFA), hemagglutination (HA), fluorescence polarization immunoassay (FPIA), and microtiter plate assays (*i.e.*, any assay done in one or more wells of a microtiter plate). One assay of the invention includes a reversible flow chromatographic binding assay, which may be performed, for example, by using a SNAP® device. *See* U.S. Pat. No. 5,726,010.

[099] In some embodiments, the method of the invention facilitates sandwich or competition-type specific binding assays. In a sandwich assay, antigen capture reagents are immobilized in a reactive zone. These antigen capture reagents may specifically bind to antigens in the sample being tested for roundworm. Following binding of the antigen from the sample, the antigen capture reagent/antigen complex is detected by any suitable method. For example, the complex may be reacted with labeled specific binding reagents (*e.g.*, an enzyme-antibody conjugate) and antigen detected (*e.g.*, upon reaction with substrate).

[0100] In other embodiments of the method of the present invention, a competition assay is performed. In a competition assay, antigen capture reagents are immobilized at

the reactive zone and are contacted simultaneously with antigen from a sample and labeled antigen (*e.g.*, an antigen-enzyme conjugate). The amount of label detected at the reactive zone is inversely proportional to the amount of antigen in the sample.

[0101] In some embodiments of the method, antibodies specific for a roundworm antigen or antigens are attached to a solid phase or substrate. A sample potentially including an antigen from roundworm is added to the substrate. Antibodies that specifically bind roundworm are added. The antibodies may be the same antibodies used on the solid phase or they may be from a different source or species. Further, these antibodies may be linked to an indicator reagent, such as an enzyme conjugate. Wash steps may be performed prior to each addition. A chromophore or enzyme substrate may be added and color may be allowed to develop. The color reaction may be stopped and the color may be quantified using, for example, a spectrophotometer, and/or the color may be subjectively assessed by the human eye.

[0102] In other embodiments of the method, antibodies specific for a roundworm antigen or antigens are attached to a solid phase or substrate. A sample potentially including a roundworm antigen is added to the substrate. Second anti-species antibodies that specifically bind antigens of roundworms are added. These second antibodies are from a different species than are the solid phase antibodies. Third anti-species antibodies that specifically bind the second antibodies and that do not specifically bind the solid phase antibodies are added. The third antibodies may include an indicator reagent, such as an enzyme conjugate. Wash steps may be performed prior to each addition. A chromophore or enzyme substrate may be added and color may be allowed to develop. The color reaction may be stopped and the color may be quantified using, for example, a spectrophotometer, and/or the color may be subjectively assessed by the human eye.

[0103] In a specific example, the method of the present invention is performed in conjunction with a device that is a lateral flow assay device by adding a prepared mammalian sample to a flow matrix of the device at a first region (a sample application zone). The prepared sample is carried in a fluid flow path by capillary action to a second

region of the flow matrix where a particulate label capable of binding and forming a first complex with an antigen in the sample exists. The particulate label can be, *e.g.*, a colored latex particle, dye sol, or gold sol conjugated to an antibody specific for a roundworm antigen. The first complex is carried to a third region of the flow matrix where an antibody that specifically binds a roundworm antigen is immobilized at a distinct location. A second complex is formed between the immobilized antibody and the first complex. The particulate label that is part of the second complex can be directly visualized by the human eye.

[0104] Roundworm antibody may be an immobilized antigen capture reagent in a reaction zone (solid phase). A second antigen capture reagent, *i.e.*, a second roundworm antibody that has been conjugated to a label, either may be added to the sample before the sample is added to the device, or the second antigen capture reagent can be incorporated into the device. For example, the labeled antigen capture reagent may be deposited and dried on a fluid flow path that provides fluid communication between a sample application zone and the solid phase. Contact of the labeled antigen capture reagent with the test sample can result in dissolution of the labeled antigen capture reagent.

[0105] In one embodiment of the method of the present invention, roundworm antigen is detected by ELISA. Specific examples of the ELISA method of the present invention is described in the Example section included herein. Although the present invention is described with respect to those specific ELISA methods, however, it is to be understood that those of ordinary skill in the art will recognize that alternative, additional or substitute ELISA steps may be used without deviating from the basic goal achieved through this method of the invention.

[0106] In another embodiment of the present invention, roundworm antigen is detected by using a lateral flow device, such as a SNAP® device, for example.

[0107] Further, the methods of the invention for detection of roundworm infection can be combined with other diagnostic assays to detect the presence of other organisms or

conditions. For example, assays of the invention can be combined with reagents that detect one or more non-roundworm worm fecal parasites, one or more non-worm fecal parasites, one or more viruses, one or more fungi, one or more bacteria, one or more blood-borne parasites or occult blood or a combination thereof. By providing two or more unique binding sites in a single assay device (such as, for example, two unique spots on a SNAP® assay device), the present invention allows for detection of two or more organisms from a single sample. In one embodiment, there are three unique spots for detection of past or present infection or infestation from three organisms (the spots being either antigen or antibody binding reagents) from a single sample (*i.e.*, the same individual sample is exposed to the three capture reagents on a single device). In yet another embodiment, there are four unique spots for detection of past or present infection or infestation from four organisms (the spots being either antigen or antibody binding reagents) from a single sample (*i.e.*, the same individual sample is exposed to the four capture reagents on a single device). It is to be understood, however, that the same device may include more than four unique spots and/or allow for the detection of more than four organisms.

[0108] The reagents for the detection of one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, or one or more bacteria may be, for example, one or more antibodies or one or more antigens recognized by antibodies specific for one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, or one or more bacteria.

[0109] When a device of the present invention includes reagents for the specific detection of hookworm and reagents for the specific detection whipworm, for example, in addition to the reagents for detecting roundworm, the method of the present invention may involve using that device for the additional purpose or purposes of determining whether the sample that is being tested for roundworm also includes hookworm and/or whipworm. In this arrangement, therefore, the method/device of the present invention would not only be able to specifically confirm that roundworm is present in or absent from any particular test sample, but it would also be useful for specifically confirming

that the sample includes or does not include any antigen of hookworm and/or any antigen of whipworm. The capability to specifically detect roundworm and one or more other organisms by applying a single sample to the device of the invention would be useful to the caregiver of the animal from which the sample under test was obtained. A caregiver who learns that a sample includes both roundworm and whipworm, but not hookworm, for example, could use that knowledge to treat the mammal from which the sample was taken specifically for roundworm by administering to that mammal a drug optimally effective against roundworm and a second drug optimally effective against whipworm. Absent such knowledge, the caregiver may, for example, otherwise treat the mammal with a drug that is optimally effective against only roundworm, only whipworm, or neither roundworm nor whipworm (in such cases, the mammal would be at risk of receiving suboptimal treatment). In addition, humans who may come in contact with the infested animal or its excretions may be advised to take precautions against acquiring the parasite or parasites. In this context, it is important to determine the worm species with high specificity, as some helminths, such as roundworms and hookworms, can cause significant disease (*e.g.*, larval migrans, severe enteritis or allergic reactions) in humans, while it is generally accepted that whipworm does not play a zoonotic role of importance in humans.

[0110] The method further may optionally include using one or more nucleic acids from roundworm, including, but not limited to, the nucleic acids of the present invention, to determine the presence or absence of roundworm in a mammalian sample. Such use of these nucleic acids for determining the presence of roundworm may be carried out before, after or concomitantly with the carrying out of any other aspects of the method, including the detection of roundworm by antibody. Therefore, in one aspect, after roundworm is detected or not detected in a particular sample and the mammal from which the sample was obtained is diagnosed as either having or not having a roundworm infection, the sample (or a later-obtained sample from the diagnosed mammal) may be tested for the presence or absence of any one or more of the nucleic acids, including any one or more nucleic acids of the invention. Anyone failing to detect roundworm in a particular mammal by using one or more nucleic acids (after the roundworm had been detected by

using one or more antibodies) would need to take into consideration the possibility that the antibodies had detected roundworm antigen prior to the appearance of detectable roundworm nucleic acid in the sample. In such an instance, the mammal's caregiver may elect to ignore the observation that the nucleic acid had failed to detect the roundworm and proceed with treating the mammal specifically for roundworm infection based on the observation that the antibodies had in fact detected roundworm. In another aspect, the nucleic acids are used to determine the presence or absence of roundworm in a particular mammal, and then the presence or absence of roundworm is further evaluated by using the antibodies of the present invention. Detection of one or more roundworm nucleic acids may be carried out by using any nucleic acid detection techniques known to the skilled artisan. For example, such detection may be carried out by performing a PCR-based technique, such as, but limited to, for example, a real-time PCR-based technique. Exemplary PCR-based techniques are described in, *e.g.*, *PCR Protocols (Methods in Molecular Biology)*, 2nd ed., Bartlett and Stirling, eds., Humana Press (2003); and Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (2001); each one of which is incorporated herein by reference in its entirety.

[0111] The present invention is specifically described with reference to six Examples; however, it is not to be construed as being limited thereto.

EXAMPLES

[0112] [Unless otherwise indicated, the following materials and techniques were used to generate data described in one or more of Examples 1-7 as described below.

[0113] Polyclonal antibody preparation. The polyclonal antibody "anti-DIV6716 pAB" (IgG) was raised in rabbit against a polypeptide having amino acid sequence corresponding to SEQ ID NO:5 and purified from serum by using standard methods. Briefly, nucleotides 50 through 427 of SEQ ID NO:1 were cloned in-frame into a vector (D8223, which is a derivative of pUC19) to create the plasmid D8339. Specifically, the 129 amino acids of SEQ ID NO:5 that follow the methionine residue at the N-terminus of

that sequence correspond to a portion of SEQ ID NO:3 and are encoded for by the cloned portion of SEQ ID NO:1. In the D8339 plasmid, the N-terminal methionine residue was encoded for by vector sequence at the junction of that plasmid where the vector was ligated to the cloned sequence from SEQ ID NO:1.

[0114] DNA sequence encoding SEQ ID NO:5 was then cleaved from the D8339 plasmid by restriction exonuclease digestion (NdeI and BamHI) and purified. This purified sequence was then ligated to linearized expression vector, pET28a, and the resulting circular construct (pTDX204::DIV6716) was transformed into BL21 (DE3) *E. coli* cells. (The complete sequence of the insert was confirmed by DNA sequence analysis.) Expression of His-tagged fusion protein was induced by addition of 1 mM IPTG to cultures of the transformed *E. coli*. Recombinant protein was solubilized in 6 M urea and purified by nickel affinity and ion exchange chromatography. (This recombinant protein is hereinafter is referred to as “rDIV6716”.)

[0115] After rDIV6716 was introduced into rabbits, anti-DIV6716 pAB was purified from the plasma of the immunized rabbits by isolating IgG antibody by protein G affinity chromatography. The polyclonal antibody anti-DIV6716 pAB was used in all six Examples described herein.

[0116] Infection and anti-helminth treatment of canine and feline animals. Parasitic nematode infection was effected by orally administering about 150-300 larvated eggs of either roundworm (*Toxocara*), hookworm (*Ancylostoma canium*), or whipworm (*Trichuris vulpis*) to a healthy canine or feline. (Specifically, *T. canis* was the roundworm that was administered to canine and *T. cati* was the roundworm that was administered to feline.) For Example 2, fecal samples were collected from canines known to be naturally infected with heartworm (*Dirofilaria immitis*). Further, for Examples 4 and 6 only, canines were treated at post-infection day 91 with Interceptor® (milbemycin oxime), which is an anthelmintic agent commercially available from Novartis Animal Health Inc. of Basel, Switzerland, or felines were treated at post-infection day 56 with Drontal® (praziquantel/pyrantel pamoate), which is an anthelmintic agent commercially available from Bayer HealthCare, LLC of Shawnee Mission, KS,

according to the manufacturer's protocol. It is well known by those of ordinary skill in the art that Interceptor® and Drontal® are effective for the removal of roundworms (and other parasitic worms) from canines and felines, respectively, within 72 hours after treatment. Infection was confirmed by microscopic observation of worm ova in fecal samples obtained from these host animals.

[0117] Canine and feline fecal sample preparation. Canine and feline animals known to be free of parasitic worm infection or to be infected with one of either roundworm, hookworm, whipworm or heartworm provided the source of fecal samples. Samples (approximately 1 gram) from frozen, unpreserved canine or feline fecal samples were suspended in 4 ml of diluent solution ("diluent solution" is 0.05 M Tris base; 1 mM EDTA; 0.45% Kathon; 16 mg/ml gentamicin sulfate; 0.05% Tween-20; 40% fetal bovine serum; 10% rabbit serum; and 5% mouse serum). The suspension was centrifuged at 4000 rpm for 20 minutes to produce a first supernatant. The first supernatant was centrifuged at 12000 rpm for 5 minutes to produce a second supernatant, which is referred to herein as "fecal extract".

[0118] ELISA assays. Purified anti-DIV6716 pAB (100 µl/well for all Examples; 10 µg/ml for each Example but Example 3, and 3 µg/ml for Example 3) was immobilized by physical adsorption on Immulon 1B 96-well plates overnight at 4°C. The plates were then blocked with 1% BSA in 0.1M Tris pH 7.0 at 4°C overnight, followed by drying at room temperature. Approximately 100 µl of fecal extract was added to each well and allowed to incubate at room temperature for one hour. The wells were then washed five times with a PBS-Tween-20 solution according to standard methods known to those of ordinary skill in the art. In a separate reaction vessel, free anti-DIV6716 pAB was labeled with horseradish peroxidase (HRP) by using the crosslinker succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC) to create a conjugate, and 10 µg/ml of this conjugate was added to each well having immobilized anti-DIV6716 pAB. Following a 30-minute incubation period at room temperature, unbound conjugate was washed from the wells by using PBS-Tween-20 solution according to standard methods known to those of ordinary skill in the art. 50 µl of TMBLUE® peroxidase substrate

(SeraCare Life Sciences, West Bridgewater, MA) was then added to each well and the plates were incubated for 10 minutes at room temperature. After stopping each enzymatic reaction with 0.1% sodium dodecyl sulfate (SDS) following the 10-minute incubation period, the optical density (OD) value of each well of the 96-well plate was measured at A650 by standard spectrophotometric techniques by using an ELISA plate reader to generate an “OD650 value” (or, more simply, an “OD value”) for each well. In this arrangement, the OD value obtained for any particular well of the 96-well plate was directly proportional to the amount of specifically bound antigen present in the well.

EXAMPLE 1

[0119] Anti-DIV6716 pAB specifically binds roundworm in fecal samples obtained from roundworm-infected canines.

[0120] It was a goal of Example 1 to determine whether anti-DIV6716 pAB specifically binds roundworm coproantigen in canines. Measured OD values for fecal samples obtained from individual canines that were known to have a roundworm-infection are shown in FIG. 7. Specifically, these samples correspond to the roundworm-infected canines that are identified as “round+SPY”, “round+QKZ”, “round+KWZ”, “round+WHY” and “round+RYZ” in FIG. 7. In this Example, an OD value also was measured for whole *Toxocara canis* extract (“Whole *Toxocara*”; added to the plate at 1 µg/ml) and for rDIV6716 (added to the plate at 1 µg/ml), which served as positive controls. (Specifically, the whole *Toxocara* extract was prepared as described in US Patent Application No. 11/763,592, assigned to the assignee of the present invention, which is incorporated herein by reference in its entirety.) Further, an OD value was measured for each one of two fecal extracts obtained from two canines that did not have a parasitic worm infection (“negTIY” and “negSVY”) and for a sample that did not contain any fecal extract (“Diluent Only”). (These latter three samples served as negative controls.)

[0121] The measured OD value of the fecal extract obtained from the negTIY and negSVY canines was 0.10 and 0.13, respectively, and the measured OD value of the

diluent only sample was 0.05. (The average OD value for these negative control samples therefore was 0.09.) The anti-DIV6716 pAB therefore was considered to not have specifically bound antigen in any one of these negative control samples.

[0122] Conversely, the average of the measured OD values of the samples obtained from the “round+SPY”, “round+QKZ”, “round+KWZ”, “round+WHY” and “round+RYZ” canines was 1.97, which was more than 21 times higher than the average OD value measured for the three negative control samples. These data indicate that anti-DIV6716 pAB specifically binds one or more roundworm coproantigens.

EXAMPLE 2

[0123] Anti-DIV6716 pAB specifically binds roundworm coproantigen, but does not specifically bind coproantigen from either hookworm, whipworm or heartworm.

[0124] It was a goal of Example 2 to determine whether anti-DIV6716 pAB specifically binds coproantigen of hookworm and/or whipworm in canines. Measured OD values for pooled canine fecal extracts are shown in FIG. 8. Specifically, these fecal extracts were derived from fecal samples obtained from five canine animals known to be infected with roundworm (“Roundworm-infected”), two canine animals known to be infected with hookworm (“Hookworm-infected”), and five canine animals known to be infected with whipworm (“Whipworm-infected”). Additionally, OD values were also measured for whole *Toxocara canis* extract (“Whole *Toxocara*”; 1 µg/ml) and rDIV6716 (1 µg/ml), which served as positive controls, and for a pooled sample of fecal extracts obtained from five canines known to be free of parasitic worm infection (“Uninfected”) and for a sample that did not contain any fecal extract (“Diluent Only”). (These latter two samples served as negative controls.)

[0125] Referring to FIG. 8, the OD value measured for each one of the hookworm-infected and whipworm-infected samples was 0.09, which approximated or equaled the measured OD values of the negative control diluent only sample (0.05) and the negative control uninfected sample (0.09). These data indicate that anti-DIV6716 pAB did not

specifically bind coproantigen in either of the samples obtained from the hookworm-infected and whipworm-infected canines.

[0126] Conversely, the measured OD value of the pooled fecal extract from the roundworm-infected canines was 0.44, which was about five times higher than obtained for the negative control samples and the hookworm-infected and whipworm-infected samples. These data indicate that anti-DIV6716 pAB specifically binds one or more roundworm antigens, but does not specifically bind any hookworm or whipworm coproantigen.

[0127] It was another goal of Example 2 to determine whether anti-DIV6716 pAB specifically binds coproantigen of heartworm in canines, as heartworms have a close phylogentic relationship with roundworms, raising the possibility of cross-reactivity. Measured OD values for individual canine fecal extracts are shown in FIG. 9. Specifically, these samples were obtained from heartworm-infected canines that are identified as “TRS 405”, “TRS 583”, and “TRS 868” in FIG. 9. In this Example, an OD value also was measured for each one of two fecal extracts obtained from two canines that did not have a parasitic worm infection (“negTIY” and “negSVY”). (These latter two extracts served as negative controls.)

[0128] Referring to FIG. 9, the average of the OD values measured for the heartworm-infected samples was 0.21 (with the largest of these OD values being 0.27), which approximated (and was actually less than) the average of the two OD values measured for the negative control samples (0.33). These data indicate that anti-DIV6716 pAB did not specifically bind any coproantigen in the samples obtained from the heartworm-infected canines.

EXAMPLE 3

[0129] Anti-DIV6716 pAB specifically binds roundworm coproantigen, but does not specifically bind coproantigen from either hookworm, whipworm or heartworm, and

specific binding of roundworm coproantigen by anti-DIV6716 pAB produces a colorimetric change that is readily observable to the human eye.

[0130] It was a goal of Example 3 to determine whether specific binding between anti-DIV6716 pAB and roundworm coproantigen while the anti-DIV6716 pAB is immobilized on a solid support can produce a colorimetric change that is observable to the human eye.

[0131] Referring to FIG. 10, anti-DIV6716 pAB (3 µg/ml) was immobilized onto the bottom surfaces of wells A1-A12 and B1-B12 of a microtiter plate as described before. Following such immobilization, the A3 and B3 wells were exposed to fecal extract from a heartworm-infected canine (indicated by “HW” in FIG. 10). The A4 and B4 wells were exposed to fecal extract from a first hookworm-infected canine, the A5 and B5 wells were exposed to fecal extract from a second hookworm-infected canine, and the A6 and B6 wells were exposed to fecal extract from a third hookworm-infected canine. The A7 and B7 wells were exposed to fecal extract from a first roundworm-infected canine, the A8 and B8 wells were exposed to fecal extract from a second roundworm-infected canine, and the A9 and B9 wells were exposed to fecal extract from a third roundworm-infected canine. The A10 and B10 wells were exposed to fecal extract from a first whipworm-infected canine, the A11 and B11 wells were exposed to fecal extract from a second whipworm-infected canine, and the A12 and B12 wells were exposed to fecal extract from a third whipworm-infected canine. The A1 and B1 wells were exposed to rDIV6716 (1 µg/ml), and therefore those wells served as positive controls. The A2 and B2 wells were not exposed to any fecal extract or to rDIV6716, and therefore those wells served as negative controls.

[0132] Following incubation of all of these wells with TMBBLUE® peroxidase substrate and the subsequent addition of the SDS, colorimetric change was visually observed in each one the wells that had been exposed to fecal extract from roundworm-infected canines (A7-A9 and B7-B9), but no colorimetric change was observed in any of the wells

that had been exposed to fecal extract from canines infected with either hookworm, whipworm or heartworm.

[0133] These data indicate that anti-DIV6716 pAB detects roundworm sufficiently enough to produce a colorimetric change that is robust and readily visible to the human eye. Further, these data indicate that such colorimetric change allows the human eye to readily distinguish roundworm-positive fecal samples from those that do not contain roundworm, including those that include one or more of hookworm, whipworm, or heartworm.

EXAMPLE 4

[0134] Anti-DIV6716 pAB detects roundworm coproantigen in some canines as early as 17 days after being infected with roundworm, and anti-DIV6716 pAB does not detect roundworm in feces of canine animals that have had a roundworm infection, but that have been rid of that infection by the time the feces were excreted by the canines.

[0135] It was a goal of Example 4 to determine whether anti-DIV6716 pAB can detect roundworm coproantigens in at least some roundworm-infected canines before roundworm ova first appear in the feces of those canines. It was another goal of Example 4 to determine whether anti-DIV6716 pAB detects roundworm in feces of canine animals that have been rid of a prior roundworm infection.

[0136] Toward these goals, OD values were measured for fecal samples obtained from five canines and are shown in FIG. 11. These canines, which are identified as “QKZ”, “RYZ”, KWZ”, “SPY” and “WHY”, were infected with roundworm on day 0 and were treated with the Interceptor® anthelmintic agent on day 91 after the administration of the infection as described before. Fecal samples were taken from all or some of these canines on day 0, on day 2 and day 111 following the administration of the roundworm infections to these animals, and on selected days between day 2 and day 111. Microscopic observation of the fecal samples from the first set of canines confirmed that

each one of the samples taken at day 0 through day 31 and at day 100 through day 111 was substantially free of roundworm ova, and that, with one exception, such ova were present only in the samples at each one of days 38 through 97. (The lone exception being that ova were not observed in the day 38 fecal sample from the KWZ canine.)

[0137] Referring to FIG. 11, the average OD value measured for these five canines at day 17 was 0.35, which was five times higher than was the average of the OD values (0.07) that were measured for those canines at day 0. Further, the specific OD value that was measured for the WHY canine at day 17 (which was 0.78) was more than 11 times higher than was the average of the OD values that were measured for all five canines at day 0, and the specific OD values that was measured for the WHY canine at days 23 and 31 (0.18 and 0.29, respectively) were more than two and more than four times higher, respectively, than was the average of the OD values that were measured for all five canines at day 0. These data indicate that, in some cases, anti-DIV6716 pAB can detect roundworm in feces from a roundworm-infected canine as early as 17 days after the canine first became infected with roundworm.

[0138] With continuing reference to FIG. 11, the OD values measured for the fecal samples taken from the five canines at days 38 through 93 were many times higher than were the OD values measured for fecal samples from those same canines following their treatment with the anthelmintic agent. These data indicate that anti-DIV6716 pAB does not detect roundworm in feces from a canine that has been rid of a prior roundworm infection.

EXAMPLE 5

[0139] Anti-DIV6716 pAB specifically binds roundworm antigen in fecal samples obtained from roundworm-infected feline animals.

[0140] It was a goal of Example 5 to determine whether anti-DIV6716 pAB specifically binds roundworm coproantigen in felines.

[0141] OD values measured for fecal samples obtained from uninfected felines and roundworm-infected felines are shown in FIG. 12. Specifically, these OD values were measured from fecal samples taken from five different roundworm-infected felines (represented by the identifiers “C085”, “C087”, “C096”, “C0100” and “C0104”) 40 days following administration of a roundworm infection to those felines. As a negative control, OD values also were measured from a fecal sample obtained from the C085 feline one day prior to the administration of the roundworm infection to that feline (“day -1”).

[0142] Referring to FIG. 12, the OD value measured for the uninfected feline (C085 at day -1) was 0.06, whereas the average OD value of the five felines at day 40 was 1.76. The average OD value measured from the fecal samples obtained from the five felines at day 40 therefore was almost 30 times greater than was the OD value measured for the uninfected feline. These data indicate that anti-DIV6716 pAB specifically binds one or more roundworm coproantigens in feline.

EXAMPLE 6

[0143] Anti-DIV6716 pAB does not detect roundworm in feces of feline animals that have had a roundworm infection, but that have been rid of that infection by the time the feces were excreted by the felines.

[0144] It was a goal of Example 6 to determine whether anti-DIV6716 pAB detects roundworm in feces of feline animals that have been rid of a prior roundworm infection.

[0145] OD values measured for fecal samples obtained from a first set of six felines and a second set of six felines are shown in FIG. 13 and 14, respectively. The first set of felines, which are identified as “C96”, “C100”, “C107”, “C85”, “C87” and “C104”, were infected with roundworm on day 0 and were treated with the Drontal® anthelmintic agent on day 56 after the administration of the infection as described before. Fecal

samples were taken from all or some of the first set of felines on day 0, day 1 and day 77 following the administration of the roundworm infections to these animals, and on selected days between day 1 and day 77. Microscopic observation of the fecal samples from the first set of felines confirmed that each one of the samples taken at day 0 through day 26 and at day 60 through day 77 was substantially free of roundworm ova, and that such ova were present in each one of the day 34 through day 54 samples.

[0146] The second set of felines, which are identified as “C91”, “C97”, “C106”, “C81”, “C98” and “C118”, were never infected with roundworm (and therefore served as negative controls). Fecal samples were taken from each one of these felines on the day that the first set of felines were infected with roundworm (day 0). Further, fecal samples were taken from these second set of felines on day 1 and day 74 following the administration of the roundworm infections to the first set of felines, and on selected days between day 1 and day 74. Microscopic observation of the fecal samples from the second set of felines confirmed that each one of the samples taken at day 0 through day 74 was free of roundworm ova.

[0147] Referring to FIG. 13, the OD values measured for the fecal samples taken from the first set of felines (*i.e.*, the felines that were infected with roundworm) at days 34 through 54 were many times higher than were the OD values measured for fecal sample samples from those same felines following their treatment with the anthelmintic agent. Further, the OD values measured for the fecal samples taken from the first set of felines at days 34 through 54 were many times higher than for each one of the negative control samples of FIG. 14. These data further indicate that anti-DIV6716 pAB does not detect roundworm in feces from a feline that has been rid of a prior roundworm infection.

EXAMPLE 7

[0148] A truncated version of DIV6716, Copro6716, is present in *T. canis* infected canine feces

A. Canine Fecal Sample Preparation

[0149] Canine animals known to harbor a roundworm (*T. canis*) infection or to not have a parasitic worm infection provided the source of fecal samples. A sample of frozen, unpreserved canine feces pooled from roundworm-infected or uninfected canines was suspended in 4 ml of extraction buffer ("extraction buffer" is 1X phosphate-buffered saline (PBS), pH 7.0-7.5 with 0.05% Tween-20). This suspension was vortexed for 2 minutes and then was centrifuged at 13,000 rpm for 25 minutes to produce a first supernatant. This first supernatant was then centrifuged at 10,000 rpm for 5 minutes to produce a second supernatant. This second supernatant hereinafter is referred to as "fecal extract".

B. Ion exchange

[0150] Ion exchange chromatography can enrich Copro6716 from a fecal sample. Fecal samples from experimentally roundworm infected and non-infected control animals were used for this study.. Fecal sample was extracted first with PBST (0.05% Tween 20), pH 7.3. Sample was diluted with sodium acetate buffer, pH 4.5 and then the pH was adjusted to 4.5 with HCl. Finally, sample was centrifuged and the supernatant was loaded onto a sulfopropyl (SP) column (HiTrap SP Sepharose column, GE Healthcare). The SP column was eluted with 50 mM sodium acetate buffer, pH 4.5 with 1 M NaCl, and the elution fractions were evaluated by ELISA. The ELISA plate was coated with rabbit anti-DIV6716 IgG at 3 µg/ml. Based on the results shown in Figure 15, it is clear that Copro6716 can be partially purified and enriched by eluting the SP column with sodium acetate buffer with 1 M NaCl. Fractions containing Copro6716 eluted in a broad peak. The end of the elution peak was not found. (Figure 15).

C. Western blotting and SDS-PAGE

[0151] Western blotting and SDS-PAGE gel showed that the molecular weight of Copro6716 is about 10 kD. Elution fractions from the SP column were mixed and buffer pH was adjusted to 7.2 with NaOH before loading onto an affinity column, which was prepared by linking the protein G purified rabbit anti-DIV6716 IgG with AminoLink resin (Pierce, Thermo Scientific). The column was washed with PBS buffer, pH 7.2, and

eluted with glycine-HCl buffer, pH 2.5, according to manufacturer's instructions. Elution fractions were loaded to a 10 well 4-12% Bis-Tris gradient gel and transferred to nitrocellulose membrane for western blotting. Probed with rabbit anti-DIV6716 IgG-HRP, western blotting showed that Copro6716 is about 10 kD (Figure 16), which is about about 2/3 of the size of full-length DIV6716 (the apparent MW of the full-length recombinant DIV6716 on SDS-PAGE is about 16 kD; data not shown). After further concentration, the same samples were visualized on an SDS-PAGE gel with Imperial Protein Stain (Pierce, Thermo Scientific). A 10 kD band corresponding to the size indicated by anti-6728IgG-HRP was visible (data not shown).

D. Mass spectrometry analysis

[0152] Mass spectrometry analysis on the band cut from the SDS-PAGE gel indicated that this band contains Copro6716, and that the C-terminal portion of DIV6716 contains Copro6716.

[0153] The 10 kD band that corresponds to the 10 kD band on the western blot was cut out from the SDS-PAGE gel and sent to the Keck Center at Yale University for mass spectrometry analysis. The sample in the gel was first trypsin digested and then analyzed by LC-MS/MS using the Q-T of Ultima Mass spectrometer (Waters). Four specific peptides were found in the sample by Mass Spectrometry analysis: Peptide 1: IMHYEHLLEGDAK (SEQ IS NO:8), Peptide 2: HEATEQLK (SEQ ID NO:9), Peptide 3: DSGASKDELK (SEQ ID NO:10), and Peptide 4: VEEALHAVTDEEK (SEQ ID NO:11).

[0154] Alignment analysis on the sequences of DIV6716 (SEQ ID NO:5) and the four peptides identified by MS analysis indicated that two peptides originated from a central portion of the DIV6716 and the other two peptides originated from the C terminal half of the full-length DIV6716, confirming that the 10 kb band identified by Western blot is derived from DIV6716. Therefore, the mass spectroscopy data is consistent with the apparent molecular weight of Copro6716 as measured by gel electrophoresis. Figure 17

shows the full-length sequence of DIV6716 (SEQ ID NO:5) with the four peptides identified by MS analysis highlighted in the shaded boxes.

[0155] The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms, while retaining their ordinary meanings. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.

[0156] A number of examples to help illustrate the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the claims appended hereto.

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence at least 80% identical to SEQ ID NOs: 3, 4, 5, 6, 7 or Copro6716.
2. The isolated polypeptide of claim 1, comprising an amino acid sequence at least 85% identical to SEQ ID NOs: 3, 4, 5, 6, 7 or Copro6716.
3. The isolated polypeptide of claim 1, comprising an amino acid sequence at least 90% identical to SEQ ID NOs: 3, 4, 5, 6, 7 or Copro6716.
4. The isolated polypeptide of claim 1, comprising an amino acid sequence at least 95% identical to SEQ ID NOs: 3, 4, 5, 6, 7 or Copro6716.
5. The isolated polypeptide of any one of Claims 1-4, wherein the polypeptide is a roundworm polypeptide.
6. The isolated polypeptide of any one of Claims 1-5, wherein the polypeptide comprises SEQ ID NOs: 3, 4, 5, 6, 7 or Copro6716.
7. The isolated polypeptide of any one of Claims 1-6, wherein the polypeptide has a sequence that is identical to SEQ ID NOs: 3, 4, 5, 6, 7 or Copro6716 except for conservative amino acid substitutions.
8. A purified Copro6716 polypeptide.
9. An isolated antibody wherein the antibody specifically binds to the polypeptide of any one of Claims 1-8.
10. The isolated antibody of Claim 9, wherein the antibody is obtained by immunization with the polypeptide that has the amino acid sequence that corresponds to

SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or Copro6716, or antigenic portion thereof.

11. The isolated antibody of any one of Claims 9 or 10, wherein the amino acid sequence of the polypeptide has 30 or fewer conserved amino acid substitutions to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7.

12. The isolated antibody of any one of Claims 9-11, wherein the antibody is detectably labeled.

13. An isolated antibody wherein the antibody specifically binds to a polypeptide that has an amino acid sequence that corresponds to any one of Claims 9-12, and wherein the antibody specifically binds roundworm antigen in a fecal sample obtained from a roundworm-infected mammal.

14. The isolated antibody of any one of claims 9-13, wherein the mammal is further infected with one or more of hookworm, whipworm and heartworm and the antibody does not specifically bind to any antigen from the one or more of hookworm, whipworm, or heartworm that may be present in the fecal sample.

15. An isolated polypeptide consisting of SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO: 7, or Copro6716 or an antigenic portion thereof .

16. The isolated polypeptide of Claim 15, wherein the amino acid sequence of the polypeptide has 30 or fewer conserved amino acid substitutions to SEQ ID NO:3 or SEQ ID NO:5.

17. An isolated antibody wherein the antibody specifically binds to the polypeptide of Claim 15 or 16.

18. The isolated antibody of any one of claims 15-17, wherein the antibody is obtained by immunization with the polypeptide that has the amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716 or antigenic portion thereof.
19. The isolated antibody of any one of Claims 15-18, wherein the amino acid sequence of the polypeptide has 30 or fewer conserved amino acid substitutions to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or Copro6716.
20. The isolated antibody of any one of Claims 15-19, wherein the antibody is detectably labeled.
21. An isolated antibody wherein the antibody specifically binds to a polypeptide that has an amino acid sequence that corresponds to any one of Claims 15-20, and wherein the antibody specifically binds roundworm antigen in a fecal sample obtained from a roundworm-infected mammal.
22. The isolated antibody of any one of claims 15-21, wherein the mammal is further infected with one or more of hookworm, whipworm and heartworm and the antibody does not specifically bind to any antigen from the one or more of hookworm, whipworm, or heartworm that may be present in the fecal sample.
23. A device for detecting the presence or absence of roundworm antigens from a sample; the device comprising a solid support, wherein the solid support has immobilized thereon one or more antibodies that are capable of specifically binding to a polypeptide that has an amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716 or an antigenic portion thereof .
24. The device of Claim 23, wherein the amino acid sequence of the polypeptide is a conservative variant of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716.

25. The device of any one of Claims 23 or 24, wherein the one or more antibodies are obtained by immunization with the polypeptide that has an amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716 or an antigenic portion thereof..

26. The device of any one of Claims 23-25, wherein the amino acid sequence of the polypeptide has 30 or fewer conserved amino acid substitutions to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7.

27. The device of any one of Claims 23-26, wherein the mammalian sample is a fecal sample.

28. The device of any one of Claims 23-27, wherein the one or more antibodies do not specifically bind any coproantigen derived from the group consisting of hookworm, whipworm, and heartworm.

29. The device of any one of Claims 23-28, wherein one or more of the one or more antibodies are labeled.

30. The device of any one of Claims 23-29, wherein the device is an enzyme-linked immunosorbent assay device.

31. The device of Claim 30, wherein the enzyme-linked immunosorbent assay device is a lateral flow immunoassay device.

32. The device of any one of Claims 23-31, wherein the sample is from a canine or a feline.

33. The device of any one of Claims 23-32, wherein the device further includes one or more reagents for the detection of one or more of the group consisting of: one or more

non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, and one or more bacteria.

34. A method of detecting the presence or absence of one or more roundworm antigens in a sample, the method comprising:

(a) contacting a sample from a mammal with one or more antibodies that can specifically bind to a polypeptide having amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, Copro6716 or antigenic portion thereof;

(b) forming antibody-polypeptide complexes in the presence of the polypeptides, if any, in the sample; and

(c) detecting the presence or absence of the antibody-polypeptide complexes, if any.

35. The method of Claim 34, wherein the one or more antibodies can specifically bind to a polypeptide having amino acid sequence has 30 or fewer conserved amino acid substitutions to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7.

36. The method of any one of Claims 34 or 35, wherein the one or more roundworm antigens are the polypeptide having amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716, or antigenic portion thereof.

37.. The method of any one of Claims 34-36, wherein the one or more roundworm antigens are the polypeptide that has an amino acid sequence that is a conservative variant of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716.

38.. The method of any one of Claims 34-37, wherein the sample is obtained from a mammal that is a canine or a feline.

39. The method of any one of Claims 34-38, wherein the roundworm is *Toxocara canis* or *Toxocara cati*.
40. The method of any one of Claims 34-39, wherein the sample is a fecal sample.
41. The method of any one of Claims 34-40, wherein the one or more antibodies do not specifically bind any coproantigen derived from the group consisting of hookworm, whipworm, and heartworm.
42. The method of any one of Claims 34-41, wherein the step of detecting the presence or absence of the complexes further includes the step of providing at least one secondary antibody that binds to at least one of the complexes.
43. The method of Claim 42, wherein the at least one secondary antibody is labeled.
44. The method of any one of Claims 34-43, wherein one or more of the one or more antibodies are labeled.
45. The method of any one of Claims 34-44, wherein the one or more antibodies are immobilized on a solid support.
46. The method of Claim 45, wherein the solid support forms part of an enzyme-linked immunosorbent assay device.
47. The method of Claim 46, wherein the enzyme-linked immunosorbent assay device is a lateral flow immunoassay device.
48. The method of any one of Claims 34-47, further comprising the step of contacting the sample with one or more reagents to detect one or more of the group consisting of:

one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, and one or more bacteria.

49. The method of Claim 48, wherein the reagents for the detection of any one or all of the one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi and one or more bacteria are one or more antibodies or one or more antigens recognized by antibodies specific for the one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi or one or more bacteria.

50. The method of any one of Claims 34-49, further comprising the step of determining the presence or absence of a nucleic acid from the roundworm.

51. The method of Claim 50, wherein the nucleic acid has a sequence that corresponds to all or a portion SEQ ID NO:1 or SEQ ID NO:2, or is a conservative variant of all or a portion of SEQ ID NO:1 or SEQ ID NO:2.

52. The method of Claim 51, wherein the step of determining the presence or absence of the nucleic acid is carried out by using a polymerase chain reaction (PCR)-based assay.

53. A method of diagnosing whether a mammal is infected with an intestinal roundworm infection, the method comprising the steps of:

(a) contacting a sample from a mammal with one or more antibodies that can specifically bind to a polypeptide having amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716 or antigenic portion thereof;

(b) forming antibody-polypeptide complexes in the presence of the polypeptides, if any, in the sample;

(c) detecting the presence or absence of the antibody-polypeptide complexes, if any; and

(d) diagnosing the mammal as having the roundworm infection if a roundworm antibody-polypeptide complex is present.

54. The method of Claim 53, wherein the one or more antibodies can specifically bind to a polypeptide having amino acid sequence that is a conservative variant of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716.

55. The method of any one of Claims 53 or 54, wherein the one or more roundworm antigens are the polypeptide having amino acid sequence that corresponds to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or Copro6716 or antigenic portion thereof.

56. The method of any one of Claims 53-55, wherein the mammal is a canine or a feline.

57. The method of any one of Claims 53-56, wherein the roundworm is *Toxocara canis* or *Toxocara cati*.

58. The method of any one of Claims 53-57, wherein the step of detecting the presence or absence of the antibody-polypeptide complexes further includes the step of providing at least one secondary antibody that binds to the antibody-polypeptide complexes.

59. The method of Claim 58, wherein the at least one secondary antibody is labeled.

60. The method of any one of Claims 53-59, wherein one or more of the one or more antibodies are labeled.

61. The method of any one of Claims 53-60, wherein the one or more antibodies are immobilized on a solid support.

62. The method of Claim 61, wherein the solid support forms part of an enzyme-linked immunosorbent assay device.
63. The method of Claim 62, wherein the enzyme-linked immunosorbent assay device is a lateral flow immunoassay device.
64. The method of any one of Claims 53-63, further comprising the step of contacting the sample with one or more reagents to detect one or more of the group consisting of: one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi, and one or more bacteria.
65. The method of any one of Claims 53-64, wherein the reagents for the detection of any one or all of the one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi and the one or more bacteria are one or more antibodies or one or more antigens recognized by antibodies specific for one or more non-roundworm worm parasites, one or more non-worm parasites, one or more viruses, one or more fungi or one or more bacteria.
66. The method of any one of Claims 53-65, further comprising the step of determining the presence or absence of a nucleic acid from the roundworm.
67. The method of Claim 66, wherein the nucleic acid has a nucleotide sequence that corresponds to all or a portion of SEQ ID NO:1 or SEQ ID NO:2, or is a conservative variant of all or a portion of SEQ ID NO:1 or SEQ ID NO:2.
68. The method of any one of Claims 66 or 67, wherein the step of determining presence or absence of the nucleic acid is carried out by using a polymerase chain reaction (PCR)-based assay.

69. A kit for detection of one or more roundworm antigens in a mammalian sample, the kit comprising the device of any one of Claims 23-33, and one or more reagents sufficient for the detection of the one or more antigens.

70. The kit of Claim 69, wherein the one or more reagents are selected from the group consisting of one or more indicator reagents, one or more antibody labeling compounds, one or more antibodies, one or more antigen capture reagents, one or more inhibitors, and one or more wash reagents.

```
caagaagatt tatggtgtgg cagcttcgag acgaaggagg catcacttca cgctcgaaaa      60
cagtctggac acccacctga aatggcttag ccacgagcaa aaggaggaac tgctgcaaat      120
gaagaaggac ggcaaatcga agaaggagct ccaggataag atcatgcact attacgagca      180
cctcgaaggc gatgcgaaac atgaagcaac agagcaactg aagggcggat gccgcgagat      240
tcttaagcat gttgttggcg aggagaaaagc agctgagatc aaagcactga aagattctgg      300
agcaagcaaa gatgagctta aagccaaggt cgaagaggca ctccacgcag tcaccgacga      360
agaaaagaag caacatatcg ccgaattcgg tcccgcatgc aagaagattt atggtgtggc      420
agcttcgaga cgaaggaggc atcacttcac gctcgaaaac agtctggaca cccacctgaa      480
atggcttagc cacgagcaaa aggaggaact gctgcaaatt aagaaggacg gcaaatcgaa      540
gaaggagctc caggataaga tcatgcacta ttacgagcac ctcgaaaggga tgctcctcgc      600
gctatgtatc ctgtattgac ggccttccaa cctatcacac ctgtcagtgc ggccttacat      660
tcgacgagcg tagaaagacc tgtcttccta agcagctggt aaagtactgc ggaatcccag      720
aatctggaga ggcgtcggcg gaagttggtg agtcgtacta acacagcacg ctctcgtttg      780
tgcagatggt gtgtgaaata cttttgtcag ttttcgtgt gttttaaata aataaaaaat      840
tccgtaaaaa aaaaaaaaaa aaaaa      865
```

(SEQ ID NO:1)

FIG. 1

2/17

```
atttatgggtg tggcagcttc gagacgaagg aggcatact tcaagctcga aaaaagtctg 60
gacacccacc tgaaatggct tagccacgag caaaaggagg aactgctgaa aatgaagaaa 120
gatgggaaat cgaagaagga gctccaggat aaggatgatc acttctacga gcacctcgaa 180
ggcgaatcga aacatgaagc aacagagcaa ctgaagggcg gatgccgca gatccttaag 240
catgttggtg gtgaggagaa agcagctgag atcaaagcac tgaaagattc tggagcaagc 300
aaagatgagc ttaaagccaa ggtcgaagat gcaactccac cggtcaccga agaagaaaag 360
aagcaacata tcgccgaatt tggccagca tgcaaggaaa ttttcggggg gccgggtgat 420
gttcgtcaca aacgcgaccc ttatacta atgacgcccg atgaagttgc tgaaggacta 480
agaagttaac ggtgatcgag ctttttgcaa aaactggttg atgcttttaa attcttttaa 540
gcctttttct tgtgttattt cggaattgta ccacacgaac agttagttcc gaataaagaa 600
ctgtaattat gtaaaaaaaa aaaaaaaaaa aa 632
```

(SEQ ID NO:2)

FIG. 2

```

caagaagatt tatggtgtgg cagcttcgag acgaaggagg catcacttca cgctcgaaaa      60
K K I Y G V A A S R R R R H H F T L E N      20
cagtctggac acccacctga aatggcttag ccacgagcaa aaggaggaac tgctgcaaat      120
S L D T H L K W L S H E Q K E E L L Q M      40
gaagaaggac ggcaaatcga agaaggagct ccaggataag atcatgcact attacgagca      180
K K D G K S K K E L Q D K I M H Y Y E H      60
cctcgaaggc gatgcgaaac atgaagcaac agagcaactg aagggcggat gccgcgagat      240
L E G D A K H E A T E Q L K G G C R E I      80
tcttaagcat gttgttggcg aggagaaagc agctgagatc aaagcactga aagattctgg      300
L K H V V G E E K A A E I K A L K D S G      100
agcaagcaaaa gatgagctta aagccaaggt cgaagaggca ctccacgcag tcaccgacga      360
A S K D E L K A K V E E A L H A V T D E      120
agaaaagaag caacatatcg ccgaattcgg tcccgcgatgc aagaagattt atggtgtggc      420
E K K Q H I A E F G P A C K K I Y G V A      140
agcttcgaga cgaaggaggc atcacttcac gctcgaaaac agtctggaca cccacctgaa      480
A S R R R R H H F T L E N S L D T H L K      160
atggcttagc cacgagcaaa aggaggaact gctgcaaatg aagaaggacg gcaaatcgaa      540
W L S H E Q K E E L L Q M K K D G K S K      180
gaaggagctc caggataaga tcatgcacta ttacgagcac ctcgaaaggga tgctcctcgc      600
K E L Q D K I M H Y Y E H L E G M L L A      200
gctatgtatc ctgtattgac ggccttccaa cctatcacac ctgtcagtgc ggccttacat      660
L C I L Y *
tcgacgagcg tagaaagacc tgtcttccta agcagctggt aaagtactgc ggaatcccag      720
aatctggaga ggcgtcggcg gaagttgggt agtcgtacta acacagcacg ctctcgttgg      780
tgcagatggt gtgtgaaata cttttgtcag ttttcgtgt gttttaaata aataaaaaat      840

```

(Nucleotide sequence is SEQ ID NO:1; Amino acid sequence is SEQ ID NO:3)

FIG. 3

```

atttatggtg tggcagcttc gagacgaagg aggcatactc tcacgctcga aaaaagtctg      60
I Y G V A A S R R R R H H F T L E K S L      20
gacacccacc tgaaatggct tagccacgag caaaaggagg aactgctgaa aatgaagaaa      120
D T H L K W L S H E Q K E E L L K M K K      40
gatgggaaat cgaagaagga gctccaggat aaggtgatgc acttctacga gcacctcgaa      180
D G K S K K E L Q D K V M H F Y E H L E      60
ggcgatgcga aacatgaagc aacagagcaa ctgaagggcg gatgccgcga gatccttaag      240
G D A K H E A T E Q L K G G C R E I L K      80
catgttggtg gtgaggagaa agcagctgag atcaaagcac tgaaagattc tggagcaagc      300
H V V G E E K A A E I K A L K D S G A S      100
aaagatgagc ttaaagccaa ggtcgaagat gcactccacg cggtcaccga agaagaaaag      360
K D E L K A K V E D A L H A V T D E E K      120
aagcaacata tcgccgaatt tgggccagca tgcaaggaaa ttttcggggg gccggttgat      420
K Q H I A E F G P A C K E I F G V P I D      140
gttcgtcaca aacgcgaccc ttatactaata atgacgccc atgaagttgc tgaaggacta      480
V R H K R D P Y T N M T P D E V A E G L      160
agaagttaac ggtgatcgag ctttttgcaa aaactgggtg atgcttttaa attcttttaa      540
R S *      162
gcccttttct tgtgttatct cggaattgta ccacacgaac agttagttcc gaataaagaa      600
ctgtaattat gtaaaaaaaaa aaaaaaaaaa aa      632

```

(Nucleotide sequence is SEQ ID NO:2; Amino acid sequence is SEQ ID NO:4)

FIG. 4




FIG. 5




FIG. 6A




FIG. 6B

7/17




FIG. 7

8/17




FIG. 8

9/17




FIG. 9




FIG. 10

11/17




FIG. 11

12/17




FIG. 12




FIG. 13




FIG. 14

15/17

Figure 15




Figure 16




Figure 17

MHHFTLENSLDTHLKWLSHEQKEELLQMKKDGKSKKELQDKIMHY
YEHLEGDAKHEATEQLKGGCREILKHVVGEEKAAEIKALKDSGAS
KDELKAKVEEALHAYTDELKQHIAEFGPACKKIYGVAAS (SEQ ID
NO. 5)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/57061

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07K 14/435, G01N 33/53 (2011.01)

USPC - 530/350; 435/7.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC: 530/350; 435/7.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC: 530/350; 435/7.1, 435/287.2

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Electronic data bases : PubWEST (PGPB, USPT, EPAB, JPAB); Google Scholar; GenCore sequence search (AA)

Search terms: Roundworm antigen, isolated polypeptide, DIV6716, copro6716, TBA-1, ABA-1, detection, antibody, solid phase immunoassay, ELISA, protein array, lateral-flow immunoassay, immunological homologue, Ascaris sp., Toxocara sp., Toxascaris

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y ----- A	US 2007/0053920 A1 (HEATH et al.) 8 March 2007 (08.03.2007). Especially para [0026], SEQ ID NO: 6.	1,5 ----- 23-25,34-36,53-55 ----- 2-4, 15-17
Y	US 2008/0311600 A1 (ELSEMORE et al.) 18 December 2008 (18.12.2008). Especially para [0014-0015], claim 6, claim 31.	23-25,34-36,53-55
Y	KENNEDY et al., Antigenic relationships between the surface-exposed, secreted and somatic materials of the nematode parasites Ascaris lumbricoides, Ascaris suum, and Toxocara canis. Clin Exp Immunol, March 1989, Vol 75, No 3, Pages 493-500. Especially pg 494 left col para 4, pg 496 right col para 1.	23-25,34-36,53-55
A	CHRISTIE et al., The ABA-1 allergen of the nematode Ascaris suum: epitope stability, mass spectrometry, and N-terminal sequence comparison with its homologue in Toxocara canis. Clin Exp Immunol, April 1993, Vol 92, No 1, Pages 125-32. Especially abstract, pg 130 fig 3.	8,23-25,34-36,53-55

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 March 2011 (18.03.2011)

Date of mailing of the international search report

29 MAR 2011

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/57061

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-5 and 15-17 with regards to Claim Group VI (copro6716)
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The applicant does not provide a SEQ ID NO. for full length copro6716, only providing sequence information of digested tryptic peptide fragments (SEQ ID NOs: 8-11). There is no way to ascertain the specific amino terminal or carboxyl terminal sequences of copro6716 from the application specification, making it impossible to make sequence homology comparisons with proteins available in the prior art.

3. ☒ Claims Nos.: 6-7, 9-14, 18-22, 26-33, 37-52, 56-70
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Group I: Claims 1-5, 15-17, 23-25, 34-36, and 53-55, drawn to isolated polypeptides with an amino acid sequence of SEQ ID NO:3, devices and methods of detecting said polypeptide.

Group II: Claims 1-5, 15-17, 23-25, 34-36, and 53-55, drawn to isolated polypeptides with an amino acid sequence of SEQ ID NO:4, devices and methods of detecting said polypeptide.

Group III: Claims 1-5, 15-17, 23-25, 34-36, and 53-55, drawn to isolated polypeptides with an amino acid sequence of SEQ ID NO:5, devices and methods of detecting said polypeptide.

---please see extra sheet---

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
Group I: Claims 1-5, 15-17, 23-25, 34-36, and 53-55, limited to SEQ ID NO:3
Group VI: Claims 1-5, 8, 15-17, 23-25, 34-36, and 53-55, limited to sequence of Copro6716

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/57061

Continuation of:

Box No. III Observations where unity of invention is lacking

Group IV: Claims 1-5, 15-17, 23-25, 34-36, and 53-55, drawn to isolated polypeptides with an amino acid sequence of SEQ ID NO:6, devices and methods of detecting said polypeptide.

Group V: Claims 1-5, 15-17, 23-25, 34-36, and 53-55, drawn to isolated polypeptides with an amino acid sequence of SEQ ID NO:7, devices and methods of detecting said polypeptide.

Group VI: Claims 1-5, 8, 15-17, 23-25, 34-36, and 53-55, drawn to isolated polypeptides with an amino acid sequence of Copro6716, devices and methods of detecting said polypeptide.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of each of the inventions listed as Groups I-VI is the specific polypeptide recited therein. Significant structural similarities cannot readily be ascertained among the polypeptides. Without significant structural similarities, the polypeptides do not have a shared special technical feature. In the absence of a shared special technical feature, the inventions lack unity with one another.